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Abstract 
The homeostatic regulation of amino acid (AA) concentration is essential for cellular 
maintenance, growth, and function. AA passage into and out of cells is mediated by 
the complex interactions between various amino acid transporters (AATs) at cell 
membranes. While numerous in vitro and in vivo studies have been carried out to 
investigate mechanisms underlying the transport systems, there are still many 
fundamental questions about their physiologic function that remain challenging to be 
addressed by available techniques. In the framework of this thesis, we have 
combined as well as applied computational and experimental approaches to shed 
light on the control mechanisms of cellular amino acid transport pathways, and to 
advance our understanding of their cooperation. In particular, we first established a 
systems biology approach to quantify the contributions of specific players in a 
complex cellular network of AATs functioning at single membranes. This enables the 
prediction of trans-membrane transport in response to various extracellular conditions 
in the presence of competitive substrates and/or inhibitors. We used this approach to 
characterize L-leucine (Leu) and L-phenylalanine (Phe) transporter systems of the 
Xenopus laevis oocyte expression system. We then developed a new computational 
model based on a mathematical representation of the nonlinear mechanistic kinetics 
of AATs to investigate the dynamic interactions between large neutral amino acid 
(LNAA) transporters located at the neurovascular unit (NVU) cell membranes. We 
incorporated published in vivo LNAA microdialysis (MD) measurements performed in 
the rat brain upon intraperitoneal administration of L-tyrosine and L-phenylalanine 
into our model to evaluate existing hypotheses about LAT1-mediated trans-
endothelial transport of LNAAs across the blood brain barrier (BBB). We thereby 
demonstrated that either strong asymmetric bi-directional kinetics of LAT1 in 
microvascular brain endothelial cells (MBECs) (lower affinity inside the MBECs) 
and/or an asymmetric distribution of LAT1 at both membranes of MBECs (lower 
expression at the abluminal membrane of the BBB) is required to reproduce in vivo 
observations. Finally, we employed our computational model to investigate whether 
and how the dynamics of LNAAs in the NVU might be affected by abnormal 
fluctuations of plasma Phe in phenylketonuria, which has so far not been addressable 
using standard experimental techniques. We showed that fluctuations of Phe 
concentration in the plasma can propagate across the BBB and change the dynamics 
of LNAAs, however, the induced effects vary between NVU individual compartments 
and they largely depend on indices of plasma Phe fluctuation such as mean and 
frequency for which we have provided a quantitative representation. 
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Zusammenfassung 
Die homöostatische Regulierung der Konzentration von Aminosäuren (AS) ist 
essentiell für zellulären Unterhalt, Wachstum und Funktion. AS Ein- und Austritt aus 
Zellen wird hauptsächlich über komplexe Interaktionen zwischen verschiedenen 
Aminosäuretransportern (AST) an Zellmembranen vermittelt. Obwohl eine Vielzahl 
an in vitro und in vivo Studien durchgeführt wurden, um die den Transportsystemen 
zugrundeliegenden Mechanismen zu untersuchen, gibt es immer noch viele 
fundamentale Fragen über deren physiologische Funktion, welche mit den 
verfügbaren Techniken noch immer schwierig zu untersuchen bleiben. Im Rahmen 
dieser Doktorarbeit haben wir computergestützte und experimentelle Ansätze sowohl 
kombiniert als auch angewandt, um ein Licht auf die Kontrolle der zellulären 
Aminosäuretransportwege zu werfen und um unser Verständnis über ihre 
Kooperation zu erweitern. Im Detail etablierten wir zunächst einen Systembiologie-
Ansatz, um die Beteiligungen der verschiedenen Akteure im komplexen zellulären 
Netzwerk von an einzelnen Membranen funktionierenden AST zu quantifizieren. Dies 
ermöglicht die Vorhersage von Transmembrantransport als Antwort auf verschiedene 
extrazelluläre Bedingungen in Anwesenheit von kompetitiven Substraten oder 
Inhibitoren. Wir benutzten diesen Ansatz, um die L-Leucin (Leu)- und L-Phenylalanin 
(Phe)-Transportersyteme im Xenopus laevis Oozyten-Expressionssystem zu 
charakterisieren. Wir entwickelten danach ein neues Computermodell basierend auf 
einer mathematischen Repräsentation der nichtlinearen mechanistischen Kinetik von 
AST, um die dynamische Interaktion zwischen den an den Zellmembranen der 
neurovaskulären Einheiten (NVE) befindenden Transportern von grossen, neutralen 
Aminosäuren (GNAS) zu untersuchen. Wir integrierten publizierte in vivo GNAS 
Mikrodialyse-Messungen (MD), die im Rattengehirn nach intraperitonealer 
Verabreichung von L-Tyrosin und L-Phenylalanin durchgeführt worden waren, in 
unser Model, um bestehende Hypothesen über LAT1-vermittelten 
Transendotheltransport von GNAS durch die Blut-Hirn-Schranke (BHS) zu 
evaluieren. Wir zeigten dadurch, dass entweder eine starke asymmetrische Kinetik 
von LAT1 in mikrovaskulären Hirnendothelzellen (MHEZ) (geringere Affinität 
innerhalb der MHEZ) und/oder eine asymmetrische Verteilung von LAT1 an beiden 
Membranen von MHEZ (geringere Exprimierung an der abluminalen Membran der 
BHS) nötig ist, um die in vivo-Beobachtungen zu reproduzieren. Zuletzt benutzten wir 
unser Computermodell, um zu untersuchen, ob und wie die Dynamiken der GNAS in 
den NVE von den abnormalen Fluktuationen des Blutserum-Phe bei Phenylketonurie 
beeinflusst werden könnten, was bisher nicht mit experimentellen Standardtechniken 
untersucht werden konnte. Wir zeigten, dass sich Fluktuationen der Phe-
Konzentration im Blutserum durch die BHS hindurch fortpflanzen und die Dynamiken 
der GNAS verändern können, allerdings variieren die induzierten Effekte zwischen 
den individuellen Kompartimenten der NVE und hängen hauptsächlich von 
Kennzahlen der Blutserum-Phe-Fluktuation wie Durchschnitt und Frequenz ab, für 
die wir eine quantitative Repräsentation vorgegeben haben. 
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Chapter 1   Introduction 
    Amino acid transport 
Amino acids (AA) are essential molecules in the synthesis of proteins and play crucial 
roles in energy, neurotransmitter, and other essential metabolic pathways whose 
homeostasis is tightly maintained [1]. There are twenty proteogenic AAs characterized 
with common chemical structure with both a carboxyl and an amino group attached to 
a central carbon (α-Carbon), but with the difference in the side group (side chain) 
attached to the α-Carbon (Fig. 1.1) [2]. AAs have traditionally been categorized into 
groups of essential, nonessential and conditionally essential. The nine essential AAs 
(L-phenylalanine (Phe), L-tryptophan (Trp), L-leucine (Leu), L-isoleucine (Ile), L-lysine 
(Lys), L-valine (Val), L-methionine (Met), L-threonine (Thr), and L-histidine (His)) must 
be taken from foods. The five nonessential AAs (L-alanine (Ala), L-aspartic acid 
(Asp),  L-asparagine (Asn), and L-serine (Ser) and L-glutamic acid (Glu)) can be 
synthesized in the body. On the other hand, the synthesis of six conditionally essential 
AA (L-arginine (Arg), L-cysteine (Cys), L-glycine (Gly), L-glutamine (Gln), L-proline 
(Pro), and L-tyrosine (Tyr)) is limited under specific pathophysiological conditions. 
  
 
 
 
 
 
 
Figure 1. 1.  Basic structure of an amino acid. AAs consist of an amino group, a 
carboxylic acid group, a hydrogen atom (H) and a side chain (R group) attached to 
the central alpha carbon (α-Carbon) that differs between the AAs. 
In general, since AAs cannot freely diffuse into or out of the cells, specialized 
membrane-spanning proteins, the so-called solute carriers (SLCs), have evolved to 
Amino group 
Carboxylic acid group 
H
H    
C 
R 
H
C 
O    
H
O    
N 
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group       Side chain  
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mediate their movements across barrier membranes [3].  More than 75 assigned SLC 
proteins are characterized as amino acid transporters (AATs) [4]. AATs display a broad 
substrate selectivity and have often been named according to their first or most 
important characterized AA substrate. For example, L-type AATs (i.e., LAT1/SLC7A5 
and LAT2/SLC7A8) prefer large neutral amino acids (LNAAs) (i.e., Leu, Tyr, Phe, etc.) 
or ASC-type AATs (i.e., ASCT1/SLC1A4 and ASCT2/SLC1A5) consider Ala, Ser, and 
Cys as substrate. In addition, AATs have been classified into three groups based on 
their mechanism: Uniporters that mediate the transfer of AAs with the direction of their 
concentration gradient, antiporters that exchange AAs for others across the membrane 
and symporters that cotransport AAs together with ions along the ions’ electrochemical 
gradient (i.e. sodium-dependent symporter) (Fig. 1.2). The functional cooperation 
between different uniporters, antiporters and symporters with overlapping substrate 
specificities constitutes an integrated network at single cell level in which one AA can 
inhibit and/or facilitate the movements of the others (Fig. 1.2). An overview of the 
epithelial AATs with the information about their substrate specificity, mechanism, and 
ion dependency is shown in Table 1.1 [1]. 
 
 
 
 
 
 
 
 
 
Figure 1. 2.  Diagram of the interactions between different classes of amino acid 
transporters. The diagram represents the underlying transport mechanisms for 
uniporter, antiporter and symporters and their interactions at single cell level. 
 
Uniporter 
Amino acids 
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Table 1.1 Overview of  epithelial amino acid transport systems 
      
Type cDNA SLC Amino Acid Substrates Mechanism               Ions 
A SNAT2 SLC38A2 
Gly,Pro,Ala,Ser,Cys,Gln,Asn, 
His,Met Symporter Na+ 
 SNAT4 SLC38A4 
Gly, Ala,Ser,Cys, Gln, Asn, 
Met, AA+ Symporter Na+ 
ASC ASCT1 SLC1A4 Ala,Ser,Cys Antiporter Na+ 
 ASCT2 SLC1A5 Ala,Ser,Cys,Thr, Gln Antiporter Na+ 
asc 4F2 hc/asc1 SLC3A2/SLC7A10 Gly,Ala,Ser,Cys,Thr Antiporter  
B0 B0AT1 SLC6A19 AA0 Symporter Na+ 
 B0AT2 SLC6A15 Pro, Leu, Val, Ile, Met Symporter Na+ 
B
0,+ ATB0, SLC6A14 AA0, AA+, b-Ala Symporter Na+ , Cl- 
b
0,+ rBAT/b0,+AT SLC3A1/SLC7A9 Arg,Lys,O,cystine Antiporter  
b TauT SLC6A6 Tau, b-Ala Symporter Na+ , Cl- 
Gly XT2 SLC6A18 Gly NR NR 
IMINO IMINO SLC6A20 Pro, HO-Pro Symporter Na+ ,  Cl- 
L 4F2hc/LAT1 SLC3A2/SLC7A5 
His,Met,Leu, 
Ile,Val,Phe,Tyr,Trp Antiporter  
 4F2hc/LAT2 SLC3A2/SLC7A8 AA0 except Pro Antiporter  
 LAT3 SLC43A1 Leu, Ile, Met,Phe Uniporter  
 LAT4 SLC43A2 Leu, Ile, Met, Phe Uniporter  
N SNAT3 SLC38A3 Gln, Asn, His Symporter Na+(Symporter),H(antiporter) 
 SNAT5 SLC38A5 Gln Asn, His,Ser, Gly Symporter Na+(Symporter),H(antiporter) 
PAT (Imino 
acid) PAT1 SLC36A1 Pro, Gly,Ala GABA, b-Ala Symporter H+ 
 PAT2 SLC36A2 Pro, Gly,Ala Symporter H+ 
T TAT1 SLC16A10 Phe, Tyr, Trp Uniporter  
X AG EAAT2 SLC1A2 Glu, Asp Symporter Na+ , H+ (symporter), 
 
EAAT3 SLC1A1 Glu, Asp 
 K+ (antiporter) 
 Symporter Na+,H+ (symporter), 
x- c 4F2 hc/xCT SLC3A2/SLC7A11 Glu, Cys Antiporter 
K+ (antiporter) 
 
y+ CAT-1 SLC7A1 Arg,Lys,O, His Uniporter 
Na+ (symporter with AA0) 
y+ L 
4F2hc/y+LAT1 SLC3A2/SLC7A7 Lys, Arg,Gln, His,Met,Leu Antiporter 
4F2hc/y+LAT2 SLC3A2/SLC7A6 
Lys, Arg, Gln, 
His,Met,Leu,Ala,Cys Antiporter Na+ (symporter with AA0) 
Adapted from Broer [1]. NR, not reported, AA0, neutral amino acids; AA neutral amino acids; AA+, cationic amino acids. O, ornithine; 
HO-Pro, hydroxyproline 
The AA transport network can become more difficult to understand when it comes into 
the interplay between transporters at multi-cell level (Fig. 1.3). These complexities arise 
from the fact that multiple AATs expressed at different cell membranes can be involved 
in the process of transporting a single AA. Characterizing the functional role of individual 
transporters within networks is necessary to understand AA transport related 
dysfunctions and to design appropriate treatment strategies.   
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Figure 1. 3.  Diagram of amino acid transport network at multi-cell level. The 
diagram represents different types of AAs and AATs that interact across multiple cell 
membranes  
 
Experimental approaches for studying amino acid transport networks 
The mammalian AATs are low-abundance membrane proteins whose function are 
affected by post-translational modifications. Hence, it can be a difficult task to isolate 
them in abundant quantities and identify their function in an active state. Over the last 
decades, the emergence of technologies such as radiotracer techniques, analytical 
quantification techniques (i.e. paper and liquid chromatography), DNA cloning and 
cellular overexpression methods, and also the advances in determining AATs structure 
has allowed researchers to gain more insights into the function of AATs [2, 5].  A large 
number of experimental approaches have been conducted to study physiological 
function of mammalian AA transport systems. These approaches investigate the role 
of endogenously expressed AATs using in vivo animal models and/or ex vivo 
organs/tissues/cells models and/or they characterize the activity of heterogeneously 
expressed AATs using in vitro models such as Xenopus laevis oocyte [6-11]. Although 
in vitro approaches provide the possibility of a direct investigation of AATs function as 
compared to the ex vivo and in vivo assays, they might not reflect the in vivo situation 
due to the high-level sensitivity of some AATs to the culture conditions. On the other 
hand, the in vivo and ex vivo experiments typically provide an overall picture of the AA 
transport across the tissues or organs. Furthermore, the intrinsic overlapping substrate 
Amino acids 
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specificity of multiple AATs present in the biological sample could be of a critical 
challenge for data interpretation in all approaches. For example, the interference from 
endogenous AATs can provide significant noise for the investigation of exogenous 
AATs using Xenopus laevis oocyte expression system. The review by Souba et al. 
discusses the strengths and limitations of different approaches [12].  
Modeling of trans-membrane amino acid transport processes 
The process of transport of a single amino acid by a simple uniporter transporter 
consists of four key steps: association of AA with the AAT  and construction of AA-AAT 
complex, conformational change of the complex from one side to the other side of the 
membrane, dissociation of AA from the complex, and eventually reverse 
conformational change of the unbound carrier to its initial position. In general, trans-
membrane transport processes can be represented by the law of mass action as 
applied to enzymatic reactions [13, 14]. The Michaelis-Menten rate law (MMRL) [15] 
and its variations [16] are the most widely used forms of the mass-action law after 
being simplified using steady state approximations [17]. The MMRL assumes a rapid 
binding of the substrate (AA) to the transporter (rapid equilibrium approximation), it 
considers concentration of transporter to be negligible as compared to the AA 
concentrates (free ligand approximation), and it holds where the formation of 
transported AA is linear with time and also the concentration of AA-AAT complex 
remains constant (steady state approximation) (i.e. during which the intracellular AA 
does not limit the transport of extracellular AA)[18-20]. Hence, the MMRL fairly 
represents the steady state behavior of an isolated transporter-amino acid couple. 
However, it is not sufficient to adequately describe the dynamic behavior of amino acid 
transporters where the AA uptake rate is not linear with time. To overcome this 
limitation, more recently, Panitchob et al. developed a mechanistic ''carrier'' type model 
to represent the kinetics of transporters with various transport mechanisms (i.e., 
uniporter, antiporter, and symporters)  [21, 22]. Their mathematical model is based on 
the law of mass action under quasi-steady state assumptions and provides an abstract 
representation of the process of transport of AAs with different classes of AATs [23].   
The combined use of in silico, in vitro and in vivo approaches to study 
amino acid transport networks  
Given the inherent functional complexities associated with the transport systems, it can 
be very challenging to characterize their function by relying on only pure experimental 
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approaches. On the other hand, in silico methods have shown to be of assistance to 
unravel these complexities.  
In this thesis, we integrated various computational and experimental approaches to 
gain more insights into the function of amino acid transport systems. In chapter 2, we 
introduce a combined in vitro and in silico methodology to quantify the function of 
individual AATs within a complex single cell AA transport network . We thereby 
predicted the aggregate single cell transport responses for various extracellular assays 
in the AAs, ions and competitive inhibitors under steady state conditions. We further 
establish an in silico framework based on the ''carrier'' type models to investigate AAT 
interactions through multiple cell membranes. In chapter 3, using our in silico 
framework, we describe the dynamic interactions between the large neutral amino acid 
(LNAA) transporters expressed at the membrane of different cell types composing the 
neurovascular unit (NVU) system (i.e., microvascular brain endothelial cells, astrocytes 
and neurons). We further explain how we combined our in silico model with published 
in vivo microdialysis measurements to address fundamental physiological questions 
about the bi-directional kinetics and expression pattern of LAT1 at the BBB which could 
not be investigated by available in vitro and in vivo techniques. We further employed 
our NVU-LNAA model to gain more insights into the pathophysiology of 
Phenylketonuria (PKU) disorder. In chapter 4, we provide a quantitative representation 
for the interactive cooperation between LNAA transporters involved in this disorder and 
further describe the therapeutic impact of LNAA supplementation in the control of 
disturbed concentrations of LNAAs in the cells of NVU in PKU disorder. In the following 
sections, we introduce how these integrations of in silico, in vitro and in vivo 
approaches could lead to answering fundamental biological questions about the AAT 
processes which could not be understood by available experimental techniques.    
Quantification of single cell amino acid transport network through a 
combined in silico and in vitro approach 
The cellular AA transport response is highly sensitive to extracellular AA conditions, 
and it can be influenced by changes in the concentrations of different AAs, ions, and 
inhibitors (stimuli) outside of the cell. On the other hand, various types of AATs with 
overlapping substrate specificity can be involved in the process of transporting AA into 
and out of the cell.  Hence, it can be a difficult and challenging task to accurately 
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determine the roles of individual AATs from the aggregate transport of a given 
substrate. This further motivated us to establish a systems biology methodology with 
the capability to quantify the contribution of individual AAT transporter to the overall 
transport of a given substrate. We applied our strategy to quantify Leu and Phe AAT 
systems expressed in the Xenopus leavis oocyte in vitro cell model. In chapter 2, we 
discuss our approach in more detail. In summary, the first step in our approach is to 
design appropriate extracellular conditions based on prior knowledge on the kinetics 
of individual Leu and Phe transporters (i.e. information about substrate specificity 
and/or ion sensitivity of individual AATs). The next step is to monitor the cellular 
transport response under designed extracellular medium conditions (i.e. in the 
presence/absence of competitive substrates and/or inhibitors and/or ions). The 
following step in our methodology is to construct a stimuli-response model based on 
the kinetics of individual transporters. The subsequent step is to collect stimulus-
response measurements to estimate kinetic parameters of individual transporters 
based on the global fitting method in which we consider the AAT kinetic parameters 
shared among all assay conditions. Given the estimated model parameters, the next 
step is to quantify the activity of individual AATs and finally to predict the overall cellular 
transport responses to extracellular conditions in the presence of competitive 
substrates and/or inhibitors.   
 Quantification of multi-cell amino acid transport network through an 
integrated in silico and in vivo approach 
The introduced approach in the second chapter of this thesis, however, is limited to 
characterize transport processes across single membranes under steady state kinetic 
assays (MMRL assumptions). In the second phase of this project, we develop an in 
silico model, beyond the validity region of MM approximation, to investigate dynamic 
behavior of transporters interacting through multiple cell membranes. The interplay 
between AATs expressed in the cells of the neurovascular unit (NVU) (i.e., 
microvascular brain endothelial cells (MBECs), astrocytes and neurons) is of great 
importance for proper brain function. It has been shown that the Na+-independent 
antiporter SLC7A5 (LAT1) in microvascular brain endothelial cells (MBEC) [24-26], the 
Na+-independent antiporter SLC7A8 (LAT2) in astrocytes [27-29], and the Na+-
dependent symporter SLC6A15 (B0AT2) in neurons [30-32] are the main regulators of 
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large neutral amino acid (LNAAs) homeostasis in the NVU (Fig. 1.4). LAT1 is the 
central element of NVU-LNAA system which plays a crucial role in controlling the 
homeostasis of LNAAs in the brain (Fig 1.  4). However, its bi-directional kinetic as well 
as its distribution pattern at the BBB [24-26], could not be well understood so far by 
available in vivo and in vitro standard assays [26, 33-35]. Additionally, the dynamic 
interactions between the NVU-LNAA transporters could not be sufficiently captured so 
far by experimental means. To overcome these limitations, we established a new 
computational model of NVU-LNAA homeostasis and incorporated it with the published 
in vivo microanalysis measurements carried out in rat models. This has allowed us to 
evaluate existing hypotheses about the LAT1-mediated trans-endothelial transport of 
LNAAs across the blood brain barrier (BBB). In particular, in chapter 3, we describe 
that either strong asymmetrical bi-directional kinetics of LAT1 in microvascular brain 
endothelial cells (MBECs) and/or an asymmetric distribution of LAT1 at both 
membranes of MBECs is required to reproduce the experimentally measured brain ISF 
responses to intraperitoneal (IP) L-tyrosine (Tyr) and L-phenylalanine (Phe) injections. 
Additionally, we employed our model to capture changes in LNAA levels in MBEC, 
astrocytes, and neurons upon perturbations of plasma LNAA concentrations. 
 
 
 
Figure 1. 4.  Schematic representation of the neurovascular unit (NVU) and the 
therein expressed dominant large neutral amino acid (LNAA) transporters. The 
dominant LNAA transporters in the NVU include the Na+-independent antiporter LAT1 
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(SLC7A5) in MBECs, the Na+-independent antiporter LAT2 (SLC7A8) in astrocytes and the 
Na+-dependent symporter B0AT2 (SLC6A15) in neurons. The arrows specify the LNAA 
transmembrane pathways. 
Investigation of perturbed AA transport pathways in Phenylketonuria 
disease  
In chapter 4, we further describe the employment of our in silico NVU-LNAA model 
(introduced in chapter 3) to get more insights into the perturbed dynamics of LNAAs in 
Phenylketonuria (PKU) disorder. PKU is an inherited disease characterized by 
abnormally high concentrations of the essential amino acid L-phenylalanine (Phe) in 
the systemic blood. It is caused by a deficiency in activity of phenylalanine hydroxylase 
(PAH) which also leads to the abnormally high fluctuations of plasma Phe 
concentration as compared to normal physiological conditions [36, 37]. While 
numerous studies have verified a negative correlation between blood Phe 
accumulation and cognitive outcomes, they have not clarified whether Phe fluctuations 
in plasma could affect brain functions [38]. This requires a deep understanding of 
complex and interactive competitions between Phe and LNAAs taking place through 
NVU-LNAA transporters, which could not be achieved precisely by available in vitro 
and in vivo standard methods so far. To bridge this gap, we quantified the interactive 
dynamics of Phe and competitive LNAAs (CL) from plasma into NVU individual cells. 
As described in chapter 4, we suggest that plasma Phe fluctuations can potentially 
propagate into the NVU and change the dynamics of LNAA concentrations. However, 
the induced effects vary between NVU individual compartments and they largely 
depend on plasma fluctuation Phe indices such as mean, fundamental frequency and 
amplitude-to-mean ratio for which we provide a quantitative representation. Finally, we 
employed the in silico model to explain the therapeutic impact of LNAA 
supplementation in attenuation of disturbed concentrations of Phe and CL in the cells 
of NVU in PKU disorder. 
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Chapter 2   Quantifying the relative contributions of different solute carriers to 
aggregate substrate transport  
This chapter has been published as: 
Mehdi Taslimifar , Lalita Oparija, François Verrey, Vartan Kurtcuoglu, Ufuk Olgac, and Victoria 
Makrides. "Quantifying the relative contributions of different solute carriers to aggregate substrate 
transport." Scientific reports 7 (2017): 40628.     
 Abstract 
Determining the contributions of different transporter species to overall cellular 
transport is fundamental for understanding the physiological regulation of solutes. We 
calculated the relative activities of Solute Carrier (SLC) transporters using the 
Michaelis-Menten equation and global fitting to estimate the normalized maximum 
transport rate for each transporter (Vmax). Data input were the normalized measured 
uptake of the essential neutral amino acid (AA) L-leucine (Leu) from concentration-
dependence assays performed using Xenopus laevis oocytes. Our methodology was 
verified by calculating Leu and L-phenylalanine (Phe) data in the presence of 
competitive substrates and/or inhibitors. Among 9 potentially expressed endogenous 
X. laevis oocyte Leu transporter species, activities of only the uniporters 
SLC43A2/LAT4 (and/or SLC43A1/LAT3) and the sodium symporter SLC6A19/B0AT1 
were required to account for total uptake. Furthermore, Leu and Phe uptake by 
heterologously expressed human SLC6A14/ATB0,+ and SLC43A2/LAT4 was 
accurately calculated. This versatile systems biology approach is useful for analyses 
where the kinetics of each active protein species can be represented by the Hill 
equation. Furthermore, its applicable even in the absence of protein expression data. 
It could potentially be applied, for example, to quantify drug transporter activities in 
target cells to improve specificity.  
 
Keywords: Systems biology, solute carrier, amino acid transporter, in vitro cell model    
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Introduction  
Solute carriers (SLCs) represent a large group of eukaryotic membrane transport 
proteins that control the uptake and efflux of a wide range of substrates such as 
inorganic ions, nucleotides, amino acids (AAs), neurotransmitters, sugars, purines, 
fatty acids, and thus, also drug molecules [3]. Solute carriers are ubiquitously 
expressed in all tissue and cell types, and in most organelles including lysosomes and 
mitochondria. The activities of SLC species are often highly redundant, and 
furthermore, the regulation of SLC expression and activity is frequently complex and 
influenced by numerous stimuli. Therefore, it can be difficult to accurately determine 
the roles of a particular species of SLC in the aggregate transport of a substrate. The 
goal of the work at hand was to establish a methodology that enables the quantification 
of the relative contributions to the overall transport of a given substrate by specific SLC 
species based on their enzymatic characteristics. 
Amino acids by virtue of their indispensable roles in protein, energy, 
neurotransmission, and other crucial metabolic pathways, are key physiological 
molecules. Since AAs cannot passively diffuse through intact cell membranes, 
movement across biological membranes is largely mediated by a subclass of SLCs, 
the amino acid transporters (AATs). Due to their control over AA transport across 
barrier membranes, AATs perform crucial roles in AA homeostasis. By mediating 
intestinal absorption and renal reabsorption, AATs are among the cornerstone 
regulators of AA bioavailability in humans and other mammals [1, 2, 5, 39]. To date, of 
52 assigned families of SLCs, eight (SLC 1, 6, 7, 12, 16, 25, 38, 43) are known to have 
members transporting AAs [4] . In total more than 75 SLC protein species are 
recognized as AATs [4]. All AATs function mechanistically by either simple facilitative 
diffusion (passive transport), or by sym- and/or anti-port of co-substrates such as ions 
(secondary active transport), and/or the obligatory exchange of AA pairs [2, 3]. The 
driving force for vectorial transport is provided by chemical and/or electrical gradients. 
Additionally, functional interactions between transporters operating by different 
mechanisms can give rise to cooperative amino acid transport [40, 41]. For example, 
it was shown by exogenous expression in Xenopus laevis oocytes that an obligatory 
exchanger, SLC7A8/LAT2 (LAT2), efﬂuxes intracellular AAs to AA free buffer only in 
the presence of a co-expressed facilitative transporter, SLC16A10/TAT1 (TAT1). 
Cooperative transport is accomplished when TAT1 recycles to the outside a LAT2 
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uptake substrate, e.g. L-phenylanalanine (Phe), against which LAT2 can efﬂux in 
exchange another intracellular AA[42]. The physiological functions of mammalian 
AATs (and of SLCs in general) have been commonly studied by probing responses of 
endogenous transporters in vivo in whole animals, ex vivo in organs, tissues, or cells, 
or by testing cloned wild-type or mutated transporters heterologously expressed using 
in vitro cell models [6-11]. While these approaches have yielded a large body of 
knowledge, for many studies, such as on AAT regulation or interactions, data 
interpretation can be confounded by the intrinsic complexity of the involved biological 
networks. This complexity, and the consequent difficulties for data analyses, arises 
from the fact that there are over 20 physiologically relevant AAs, and the ubiquitous 
cellular expression of multiple AAT protein species with overlapping AA specificities 
and non-mutually exclusive transport mechanisms. Meaningful analysis of these 
complex processes would be aided by a method based on AAT kinetic characteristics 
to determine the relative contributions of specific transporter species to overall 
substrate transport. 
In this study, our aims were to develop a strategy to (1) quantify the relative function of 
specific SLC species within a system of transporters with a variety of substrate affinities 
and transport mechanisms, and (2) experimentally verify the calculations for total 
transport and for responses to new stimuli (extracellular conditions) by individual 
transporter species. As a biological model we chose transporters expressed in 
Xenopus laevis oocytes for the essential neutral amino acid L-leucine (Leu) (Table 2. 
1). As an important model organism X. laevis has been extensively physically and 
biochemically characterized. Furthermore, X. laevis oocytes have been widely used for 
molecularly identifying SLCs (including AATs) and for characterizing transport kinetics 
including substrate specificities and transport mechanisms [26, 43-54]. However, while 
good data exists for expression of X. laevis oocyte endogenous AAT (xAATs) mRNA, 
little data exists about their protein expression. 
For the developed approach, the activity of specific AAT species in different 
experimental conditions were represented by the Michaelis-Menten (MM) equation. 
We estimated unknown transporter parameters by a global fitting method [55, 56] in 
which they were considered as shared parameters among all assay conditions. Model 
calculations were verified by comparison to measured AA uptake rates. Using our 
approach we (1) identified the relative activity of endogenous X. laevis AATs Leu 
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transporters in a variety of experimental conditions, (2) extended our predictions to 
successfully characterize Phe transporters, and (3) accurately calculated the 
behaviour of the heterologously expressed human sodium-dependent (Na+-dep) 
symporter SLC6A14/ATB0,+ (hATB0,+) and sodium-independent (Na+-indep) uniporter 
SLC43A2/LAT4 (hLAT4). Our approach is shown to provide a robust and versatile tool 
for unraveling the contributions of specific players in a complex cellular network of 
transporters and substrates. 
 
   Table 2. 1.    Model input parameters (Vmax and Km) for L-leucine and L-phenylalanine transporters  
 Symporters Antiporters Uniporters 
SLC no. SLC6A14 SLC6A19 SLC7A5 SLC7A8 SLC7A7 SLC7A6 SLC1A5 SLC16A10   SLC43A1         SLC43A2 
Alias ATB0,+ B0 AT1 LAT1 LAT2 y+LAT1 y+LAT2 ASCT2   TAT1     LAT3  LAT4 
Accessory 
protein  
 
coll 
TMEM27 
 
4F2hc 
SLC3A2 
4F2hc 
SLC3A2 
4F2hc 
SLC3A2 
4F2hc 
SLC3A2    
  
 
                                    Vmax (nmol/h) 
         Vmax1 Vmax2 Vmax1 Vmax2 
 
Leu 
 
0.014a  
[57] 
 
0.539 
[47] 
 
0.162 
[58] 
 
 0.402 
 [59] 
 
0.38  
[60] 
    
  1.60 
    [61] 
 
 1.01      
[62] 
NA 
 
0.0138 
 [43] 
 
 0.766 
 [43] 
 
0.0204 
[45] 
    
3.516 
[45] 
Phe 0.034
a 
[57] 
1.118 
[47] 
0.147 
[58] 
 0.27 
 [59] NA NA NA 
10
0 
[53] 
0.0076 
 [43] 
0.75 
[43] 
 
0.0204 
  [45] 
 
3.516 
   [45] 
 
                                       Km (mM) 
         Km1 Km2 Km1 Km2 
Leu 
 
0.012 
 [63] 
 
1.1 
[64] 
 
0.032 
[65] 
 
0.048 
[66] 
 
0.0317 
[60] 
 
0.236 
[61] 
 
0.367 
[62] 
NA 
 
0.0842 
[43] 
 
1.024 
[43] 
 
0.103 
[45] 
 
3.733 
[45] 
Phe 
 
0.017  
[63] 
 
4.7 
[64] 
 
0.74 
[65] 
 
 0.0122 
[66] 
NA NA NA 
 
36 
[53] 
 
0.0658 
[43] 
 
1.206 
[43] 
 
0.178 
[45] 
 
4.694 
 [45] 
Ala 
 
0.099 
[63] 
     
       4.1 
[64] 
NA 
 
 0.167 
[66] 
NA 
 
4.12 
[61] 
 
0.0184 
[62] 
NA NA NA NA NA 
Arg 
 
0.104 
[63] 
NA NA NA 
 
0.34  
[60] 
 
0.177 
[61] 
NA NA NA NA NA NA 
Trp 
 
0.026  
[63] 
 
>12 
[64] 
 
0.0214 
[58] 
 
0.0576 
[59]  
NA NA NA NA NA NA NA NA 
BCH 
 
0.52a 
[63] 
NA 0.055 [28] 
0.023 
[28] NA NA NA NA 
0.055b 
[28] 
2.5ab 
  [43] 
  0.055b 
[28] 
     28ab 
[43]  
Val 
 
0.036 
[63] 
 
1.53a 
[47] 
 
0.0472 
[58] 
 
0.124 
[59] 
NA NA 
 
0.522 
   [62] 
NA 
 
0.0306 
[43] 
 
1.885 
[43] 
 
0.0472b 
[28] 
     
 36ab 
[43] 
Sodium 
dependent 
yes yes no no     yes yes yes no no no 
Log 10 
mRNA 
4 0.6    1     2.5 3.4 3 3.5 0.8    2.4 1.5 
References for model input are given. As indicated all Vmax rates were reported as nmoles per hour (nmol/h). If the Vmax rates were not provided in units 
of nmol/h then these values were recalculated from literature reported units. a Vmax and Km values were calculated using the Michaelis-Menten equation. 
b The high affinity component was assumed to be equal to LAT1. NA (not applicable) indicates the amino acid was not reported to be a substrate for the 
transporter. The Log10 mRNA expression is taken from the reported microarray data for unfertilized X. laevis oocytes (Xenbase). The mRNA expression 
Log10 values for the accessory proteins, TMEM27/collectrin and SLC3A2/4F2hc, are 1.5 and 1.0 respectively. Standard three letter abbreviations are 
used for amino acid names; BCH is the Leu analog b(−)2-aminobicyclo[2,2, 1]heptane-2-carbocyclic acid.  
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Methods 
An overview of the systems biology approach we developed for this study and the 
generally applicable method for characterizing enzyme activities are shown in Fig. 2. 
1. The method can be applied for calculating the contributions of specific enzyme 
species to the bulk measured enzymatic activity if the MM (or Hill) equation can be 
used to describe the kinetics of the target enzyme species. In other words this method 
can be applied for analyses of steady-state (or rapid equilibrium) measurements of a 
saturable activity under conditions where (1) the enzyme concentration is well below 
the MM binding constant (𝐾𝑚  ), and (2) substrate binding (and dissociation) ocurrs 
much more rapidly than product formation (i.e. transport) [67]. 
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Figure 2.1.  Diagram of the method used for quantifying activity of specific 
transporter species. The left panel is a schematic of the steps taken in the current 
study to establish and verify the method for amino acid transport in Xenopus laevis 
oocytes. AAT refers to Solute Carrier amino acid transporters for L-leucine and L-
phenylalanine. The source for the mRNA expression data was Xenbase as described 
in Methods and Results. Uptake assay protocols are described in Methods. Defined 
uptake buffers are described in Methods, Results, and Fig. 2. The input parameters for 
the calculations are given in Table 2. 1. The rationale for the specific equations used 
to construct the current model are given in the methods. The right panel is a 
generalized series of steps that could be applied to any system where the kinetics of 
each active enzyme species can be represented by the Hill equation.  
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Experimental Procedures 
Preparation of human SLC6A14/ATB0,+ and SLC43A2/LAT4 cRNA 
The cDNA for hATB0,+ (cloned in the pSPORT1 vector) was kindly provided by Andreas 
Werner (University of Newcastle upon Tyne, Newcastle, UK).  Linearization for cRNA 
preparation was carried out using NOT1 restriction enzyme digestion (Thermo 
Scientific). Flag-tagged hLAT4 was prepared from hLAT4 cDNA (in pTLN vector) kindly 
provided by Manuel Palacin (IRB Barcelona, Barcelona Spain). The cDNA was initially 
cloned in a pLenti6-EGFP vector (Invitrogen) using NruI and MluI restriction sites and 
subsequently transferred into aFastBac-FLAG(C) vector (kindly provided by Thierry 
Hennet, University of Zurich) with the following primers: 5’-CAT GGC GCC CAC 
CCTGGC CAC TG-3’ (for) and 5’-CTA CAC GAA GGC CTC CTG GTT G-3’ (rev). The 
hLAT4-FLAG(C) insert was then cloned into a pSDeasy vector using XbaI / NotI 
restriction sites. FLAG-tagged hLAT4 in pSDeasy (referred to in text as hLAT4) cDNA 
was linearized with Pvu I restriction enzymes (Thermo Scientific) for cRNA preparation. 
The cRNAs for both human transporters were synthesized (according to the 
manufacturer’s protocol) using the MEGAscript high yield transcription kit (Ambion) 
and the T7 (hATB0,+) or SP6 (hLAT4) RNA polymerases. 
Xenopus laevis oocyte preparation 
Stage VI oocytes [68] were treated with collagenase A at room temperature in Ca2+-
free buffer (82.5 mM NaCl, 2 mM MgCl2 and 10 mM HEPES, pH 7.4) for 50-60 minutes. 
Remaining follicular layers were removed manually and non-injected (NI) oocytes were 
either tested naïve or injected with 10 ng of hLAT4 or 25 ng of hATB0,+ cRNA. Oocytes 
were incubated for three days at 16oC in modified Barth’s solution (88 mM NaCl, 1 mM 
KCl, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.33 mM Ca(NO3)2, 2.4 mM NaHCO3, 10 mM 
HEPES, 5 mg/l Gentamicin, 5 mg/l Doxycycline) before assaying [49]. 
Xenopus laevis oocyte L-amino acid radiolabelled tracer uptake assay 
Oocytes were pre-equilibrated for 2 minutes at 25°C in a sodium containing solution 
(100 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES pH 7.4 (+Na+)) 
or in the uptake assay buffers (uptake buffers) specified in Fig. 2. 2. Uptake buffers for 
specific substrates (e.g., Leu or Phe) contained defined sodium concentrations (i.e. 
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with 100 mM sodium (+Na+) vs. without Na+ (Na+free) in which Na+ was replaced with 
equimolar N-Methyl-D-glucosamine (NMDG)). Leu uptakes were carried out in uptake 
buffers without and with the addition of the following 10 mM competitive substrates: L-
alanine (+Ala), L-arginine (+Arg), 2-aminobicyclo [2.2.1]-heptane-2-carboxlate 
(+BCH), and L-tryptophan (+Trp). For uptakes, oocytes were incubated in 100 µl of 
uptake buffers containing unlabeled AA in concentrations as indicated (see text, Fig. 
2. 2 or figure legends). The [3H]-L-radiolabeled AAs (Leu or Phe) at a concentration of 
20 μCi/ml (for experiments with only non-injected (NI) oocytes), or 5 μCi/ml (for 
experiments with exogenously expressed AATs including NI controls) were added as 
tracers (Hartmann Analytic, Braunschweig, Germany) for the indicated assay times (at 
25°C). To stop the reactions, uptake buffers were removed, oocytes washed six times 
with ice-cold +Na+, and lysed individually in 2% SDS. Scintillation fluid (Emulsifier-
Safe™) was added and radioactivity counted in a liquid scintillation counter (TRI-CARB 
2900TR, Packard Instrument, Meriden, CT).  
Uptake data normalization 
The measured Leu and Phe uptake rates were normalized to the uptake rate of 1 mM 
Leu and 10 mM Phe in +Na+ uptake buffers, respectively. Experiments were routinely 
repeated for 3 or more oocyte batches (as indicated in the figure legends). Additionally, 
some experiments were performed over more than one day using the same batch of 
oocytes, therefore, normalization was carried out for data from each day experiments 
were performed, as well as for each batch of tested oocytes. 
 
Figure 2. 2. Inhibition of L-leucine transporters in tested uptake buffers L-leucine 
(Leu) uptake was tested in buffers containing 10 mM added competitors (BCH or amino 
acids). The Leu transporters (AATs) with affinity (Km (mM) values shown in Table 2. 1) 
for the added competitors are indicated in the filled cells of the same color as the text 
for the named competitors. For Na+free uptake buffers, the Na+-dependent Leu AATs 
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(i.e. require Na+ for Leu uptake) are indicated by ND. Additionally, responses of the 
Leu transporters for the competitor listed first for each uptake buffer are shown in the 
upper row and for the competitor listed second are shown in the lower row of filled 
cell(s). Clear boxes indicate AAT Leu uptake is unchanged due to addition of the 
indicated competitor and are used for AATs that transport Leu with affinities listed in 
Table 2. 1 but do not transport the added competitor. a Km (mM) value is for low affinity 
kinetic component. 
Mathematical model 
An AAT kinetic component (AATi) is defined as each unique MM binding affinity (𝐾𝑚  ) 
and maximum transport rate (𝑉𝑚𝑎𝑥 ) exhibited by an AAT species for a given substrate. 
In X. laevis oocytes there are 11 AATi for Leu transport among the 9 known Leu 
endogenous AAT (xAAT) species (Table 2. 1).  This is because SLC43A1/LAT3 (LAT3) 
and LAT4 each display a high and low affinity for Leu and thus 2 AAT i, while the 
remaining 7 xAAT species each have 1 AATi for Leu [43, 45]. The uptake rate per 
oocyte in a defined assay condition (a) carried out by all xAAT species (Vendo,a) is given 
by the sum of the uptake rates of the active xAAT species as  
 Vendo,a =  ∑  Vi,a
ni
i=1
, 
       
1 
 
where Vendo,a is the cumulative xAAT uptake rate for a given substrate (e.g., Leu) in a 
defined assay condition (including substrate concentration), Vi,a is the rate of transport 
by each exhibited AATi of the active xAAT species, and ni is the total number of AATi 
for a given substrate displayed by all active xAAT species. Assuming non-cooperative 
binding, (i.e. a Hill coefficient of 1), under steady-state conditions the transport rate for 
a given xAAT species can be defined by the MM equation as 
 Vi,a=  𝑉𝑚𝑎𝑥,i
[S]a
𝐾𝑚,i+[S]a
, 2 
Where 𝑉𝑚𝑎𝑥,i  is the maximal transport rate by a AATi of an xAAT species, provided that 
all AATi of that species are bound to the given AA, with 𝐾𝑚,i the corresponding MM 
binding constant; and [S]𝑎is the concentration of the AA in the given assay condition.  
In the presence of nI different competitive inhibitors, the rate of transport for a given 
assay condition by each xAATi is given by 
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 Vi,a = 𝑉𝑚𝑎𝑥,i  
[S]a
𝐾𝑚,i (1+∑ (
[I]a
𝐾𝐼
)
j
nI
j=0
)+[S]a
, 3 
 
where [I]𝑎 and 𝐾𝐼 are inhibitor concentration and inhibitor dissociation constant of each 
competitive inhibitor for a given AAT type (Table 2. 1), respectively.  
Using Vi,a from equation (3), then equation (1) for  cumulative uptake rate per oocyte 
in a given uptake buffer (Vendo,a) can be defined as 
 
Vendo,a =  ∑  𝑉𝑚𝑎𝑥,i  
[S]a
𝐾𝑚,i  (1 + ∑ (
[I]a
𝐾𝐼
)
j
nI
j=0
) + [S]a
 
ni
i=1
,        
4 
 
Global fitting 
In equation (4),  𝑉𝑚𝑎𝑥,i , is a free parameter that is shared between assay conditions 
and therefore assumed to be equal for all uptake buffers. Using global fitting (also 
referred to as shared parameter fitting) a single (global) value is estimated as the best 
fit for each free parameter ( 𝑉𝑚𝑎𝑥,i ) for all uptake buffers [55, 56]. The fitting process 
seeks to minimize the loss function given by the mean squared residual error (MRE) 
 1
na
∑ (Vendo,a − Vendo,a̅̅ ̅̅ ̅̅ ̅̅ ̅)
2
na
a=1
, 
5 
where na is the number of assay conditions (i.e. for 2 uptake buffers and 7 Leu 
concentrations, na=14), Vendo,a  is the cumulative uptake rate calculated based on 
equation (4) and Vendo,a̅̅ ̅̅ ̅̅ ̅̅ ̅  is the experimentally measured uptake rate by all xAATs for 
each assay condition.  
To estimate the free parameters  𝑉𝑚𝑎𝑥,i , the cumulative xAAT uptake rate, Vendo,a̅̅ ̅̅ ̅̅ ̅̅ ̅ , was 
measured for Leu transport in two uptake buffers (+Na+ and Na+free) at 7 extracellular 
Leu concentrations (0 – 1000 µM). In addition, for each experimental condition, the 
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cumulative uptake rate by xAATs, Vendo,a , was calculated based on equation (4) using 
the literature reported 𝐾𝑚 values for each AAT species (Table 2. 1). The MRE (equation 
(5)) was minimized simultaneously for all datasets using least squares optimization in 
Origin (OriginLab (2016), Origin: An industry-leading scientific graphing and data 
analysis software.  Northampton, MA, United States. URL http://originlab.com/), 
yielding the unknown parameters 𝑉𝑚𝑎𝑥,i . Based on the estimated  𝑉𝑚𝑎x,i  and the 𝐾𝑚,i  
values reported in the literature for each AAT species (Table 2. 1), the uptake rate by 
all xAAT species with previously reported mRNA expression (Xenbase) was calculated 
for 0 – 1000 µM extracellular Leu using equation (2). As a validation step, based on 
equation (4) and using the estimated  𝑉𝑚𝑎𝑥,i  and reported  𝐾𝑚,i  values (Table 2. 1), the 
cumulative uptake rate by xAATs for six uptake buffers was simulated for 0 – 1000 µM 
extracellular Leu.          
Relative expression of amino acid transporters  
The maximum transport rate for a given AA (𝑉𝑚𝑎𝑥 ) by an AAT species (or for AAT 
species with multiple kinetic components the dominant 𝑉𝑚𝑎𝑥,𝑖 ) is related to the 
(dominant) maximum turnover rate by a single AAT molecule (𝑉𝑚𝑎𝑥,s) as follows 
  𝑉𝑚𝑎𝑥  = N  𝑉𝑚𝑎𝑥,s 6 
 
where N is the total number of expressed molecules of an AAT species. To calculate 
N, we assumed that for given substrate the (dominant) maximum transport rate by 
single AAT molecule of given xAAT species 𝑉𝑚𝑎𝑥,s,endo is equal to that of the 
exogenously expressed AAT ortholog 𝑉𝑚𝑎𝑥,s,exo. Therefore, using equation (6), the level 
of expression of exogenous relative to endogenous AATs (R) is 
  R = Nexo
Nendo
=
𝑉𝑚𝑎𝑥,exo
𝑉𝑚𝑎𝑥,endo
, 7 
Where  Nexo and Nendo are the total number of exogenous and endogenous AAT 
molecules of the given AAT species, respectively. The 𝑉𝑚𝑎𝑥,endo values (corresponding 
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to dominant 𝑉𝑚𝑎𝑥,𝑖,endo) were calculated using global fitting (to solve equation (5)), 
whereas 𝑉𝑚𝑎𝑥,exo  for each xAAT ortholog was taken from the literature (Table 2. 1).  
Calculation of human SLC6A14/ATB0,+ activity 
Total uptake rate by oocytes expressing hATB0,+ (Vt,a) is given by 
  Vt,a= Vendo,a  + VhATB0,+,a , 8 
 
where Vendo,a is the rate of uptake in a given assay condition by all xAAT species (from 
equation (4)) and  VhATB0,+   is the hATB
0,+ uptake rate. Based on the MM equation 
(equation (2)), then equation (8) can be written as 
  Vt,a=  Vendo,a +  𝑉𝑚𝑎𝑥,hATB0,+  
[S]a
𝐾𝑚,hATB0,++[S]a
,  9 
 
To estimate  𝑉𝑚𝑎𝑥,hATB0,+  ,  Vt,a was determined in 2 assay conditions (10 µM and 1000 
µM Leu in +Na). Subsequently, equation (9) was fit to the data using nonlinear least 
squares fitting, employing Vendo,a  (equation (4)) and the reported  𝐾𝑚,hATB0,+   (Table 2. 
1) as the known parameters. The maximum transport rate by hATB0,+ ( 𝑉𝑚𝑎𝑥,hATB0,+ ) 
was calculated, and used in the MM equation with  𝐾𝑚,hATB0,+   (Table 2. 1) to calculate 
the hATB0,+  uptake rates from 0 – 3000 µM Leu.  
Calculation of human SLC43A2/LAT4 L-phenylalanine uptake rate 
Based on equation(7), the relationship between the maximum transport rates for Leu 
and Phe by exogenous and endogenous AATs is: 
    𝑉𝑚𝑎𝑥,i,endo,Phe  
𝑉𝑚𝑎𝑥,i,endo,Leu 
 =  
𝑉𝑚𝑎𝑥,i,exo,Phe  
𝑉𝑚𝑎𝑥,i,exo,Leu 
, 10 
where    𝑉𝑚𝑎𝑥,i,endo,Leu  is estimated by global fitting (equation (5)). The values for 
   𝑉𝑚𝑎𝑥,i,exo,Leu and    𝑉𝑚𝑎𝑥,i,exo,Phe were taken from the literature for each xAAT species 
ortholog (Table 2. 1) to calculate    𝑉𝑚𝑎𝑥,i,endo,Phe for the 6 xAAT species transporting 
both Leu and Phe (Table 2. 1). Based on the Xenbase database[69], 
xSLC16A10/TAT1 (xTAT1) mRNA is expressed by unfertilized oocytes. Furthermore, 
it is the only xAAT species potentially expressed by oocytes that transports Phe but 
not Leu. The maximum transport rate for xTAT1 was estimated using cumulative 
uptake by NI oocytes measured for 2  assay conditions (1000 µM and 10000 µM Phe 
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in +Na; equation (4)). The estimated 𝑉𝑚𝑎𝑥,𝑖 values for xSLC6A19/B
0AT1 (xB0AT1), 
xLAT4, and xTAT1 were used with the respective reported 𝐾𝑚 values for Phe for the 
orthologous AAT species (Table 2. 1) in the MM equation to calculate the uptake rates 
from 0 – 10,000 µM Phe.  
For the total uptake rate by hLAT4 expressing oocytes (as for hATB0,+), equation (8) 
can be written as 
  Vt,a=  Vendo,a + RLAT4 ∙ 𝑉𝑚𝑎𝑥,xLAT4 
[S]𝑎
𝐾m,hLAT4+[S]𝑎 
 ,                                          11 
 
where  Vendo,a   is the cumulative uptake rate by the  9 xAATi  for 7 xAAT species 
transporting Phe (equation(3)), and RLAT4 is the expression of hLAT4 relative to xLAT4 
based on equation (7). To estimate RLAT4, Vt,a was determined by uptake experiments 
using 2 assay conditions (1000 µM and 10,000 µM Phe in +Na+). Subsequently, 
equation (11) was fit to the data using nonlinear least squares fitting, employing Vendo,a  
(equation (1)),  𝑉𝑚𝑎𝑥,xLAT4  (global fitting solution of equation (5)), and the reported 
 𝐾𝑚,hLAT4  (Table 2. 1) as the known parameters, and RLAT4 as the free parameter. 
Based on the estimated RLAT4, the hLAT4 maximum transport rate ( 𝑉𝑚𝑎𝑥,hLAT4 ) was 
calculated and used in the MM equation with the reported 𝐾𝑚,hLAT4 (Table 2. 1) to 
calculate hLAT4 uptake rates from 0 – 10,000 µM Phe. All calculations were carried 
out using Origin (OriginLab (2016), Origin: An industry-leading scientific graphing and 
data analysis software.  Northampton, MA, United States. URL http://originlab.com/''.) 
Results   
Xenopus laevis oocyte endogenous L-Leucine transport  
The National Institutes of Health (NIH) supports the web based resource Xenbase [69-
71] that reports, among other information, Xenopus laevis mRNA expression data from 
microarray studies. In this study we used the Xenbase microarray data to determine 
the set of potentially expressed xAAT species in unfertilized oocytes. This search 
identified 9 SLC genes that code for Leu xAATs with mRNA expression (Table 2. 1). 
We first determined the appropriate experimental conditions for which the transport 
activity of these AAT protein species can be described by MM kinetics [67]. We 
observed that under our assay conditions, and consistent with previous reports, Leu 
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uptake rates by oocytes increased linearly for at least 8 minutes (Suppl. Fig. 2. 1). 
Therefore, subsequent experiments were carried out at 3 minutes as indicated in figure 
legends and/or text.  Leu concentration-dependence (0−1000 µM) uptake assays were 
performed using +Na+ or Na+free uptake buffers. Leu uptake in +Na+ buffers 
corresponds to uptake by both Na+-dep and Na+-indep AAT species, while the uptake 
measured in Na+free uptake buffers indicates the activity of Na+-indep AAT species 
alone (Tables 2.1 and Fig. 2. 2). A simultaneous fit (global fitting method) to the 
measured uptake responses in +Na+ and Na+free buffers was used to calculate the 
maximum transport uptake rates by the active Leu xAAT species (Fig. 2. 3A). Since 
there are no reported kinetic studies for xAAT species, 𝐾𝑚   values used in the 
calculations were taken from published reports of mammalian orthologs assayed by 
heterologous expression in X. laevis oocytes (Table 2. 1). Based on the 𝑉𝑚𝑎𝑥   values 
calculated for each xAAT species (Table 2. 2) and the respective reported 𝐾𝑚   values 
for the orthologs (Table 2. 1), the activity of xAATs was determined using the MM 
equation (Fig. 2. 3B). Although mRNA for 9 Leu xAAT species has been detected in 
unfertilized oocytes (Xenbase), we calculated that the activity of only two low affinity 
transporter species accounted for total Leu uptake. These were the sodium-dependent 
symporter xB0AT1 and the sodium-independent uniporter xLAT4, while the remaining 
xAATs were calculated to contribute minimally to Leu uptake. The activity of xLAT4 
was found to predominate throughout the range of Leu concentrations tested (10 – 
1000 µM). The calculated normalized 𝑉𝑚𝑎𝑥  (± SD) for xB
0AT1 and xLAT4 (low affinity 
kinetic component [43, 45]) was 30.7 ± 5.1 and 383.4 ± 8.7, respectively, indicating 
that the relative contribution to Leu uptake by xLAT4 was approximately 12 times that 
of xB0AT1 (Fig. 2. 3B).  
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Model verifications  
Several model verifications were performed as follows: (1) 𝑉𝑚𝑎𝑥,𝑖  for the xAATs species 
was calculated from concentration-dependence assays carried out in different uptake 
buffers (Table 2. 2), and (2) Leu uptake rate was measured in uptake buffers with 10 
mM added competitive substrates (Fig. 2. 2) and compared with the calculated model 
output. To test the dependence of the model output relative to the input data, the 𝑉𝑚𝑎𝑥,𝑖  
values calculated from 4 combinations of uptake buffers were compared with values 
from Leu uptake response in ± Na+ buffers. The mean normalized 𝑉𝑚𝑎𝑥,i values for 
xB0AT1 and xLAT4 in the 4 new buffer combinations were calculated as 32.4 ± 2.7 and 
391 ± 5, respectively (Table 2. 2). Since these values compared favorably with the 
original calculations in ± Na+ buffers (see above), further simulations were carried out 
using the normalized 𝑉𝑚𝑎𝑥,i values calculated from ± Na
+ Leu uptake response.  
Next, we checked the model calculations for Leu uptake responses by xAATs species 
in the presence of uptake buffers containing excess competitive inhibitors (Fig. 2. 2). 
Calculations of cumulative  uptake rates were carried out using the calculated 𝑉𝑚𝑎𝑥,i   
for each xAAT species and the reported 𝐾𝑚,i  values for the mammalian orthologs 
(Table 2. 1). The calculated cumulative uptake curves were compared with 
Table 2. 2.  Comparison of endogenous Xenopus laevis L-leucine transporter maximum 
turnover rates estimated using model input data from assays in various combinations of 
uptake buffers. 
 Original Test 
Experimental buffer 
conditions used as 
model input  
Leu+Na+ 
Leu+Na+free 
Leu+Na++Ala+Arg 
Leu+Na++BCH 
Leu+Na++BCH 
Leu+Na+free+Ala 
Leu+Na++Ala+Arg 
Leu+Na++BCH 
Leu+Na++BCH+Ala 
Leu+Na+ 
Leu+Na++Ala+Arg 
Leu+Na+free 
Leu+Na+free+Ala 
Vmax,xB0AT1 30.7 ± 5.1  28.2 ± 8.1 39.2 ± 4.3 27.9 ± 4.8 34.3 ± 2.5 
Vmax,xLAT4 383.4 ± 8.7 405.3 ± 16.6 372.1 ± 8.2 406.5 ± 9.4 382.0 ± 3.2 
Results are amino acid transporter maximum transport rates (normalized to uptake rate at 1 mM Leu in +Na+ buffer)  with standard 
deviations (𝑉𝑚𝑎𝑥,𝑖   ± SD). The model estimations were calculated using data generated from different combinations of uptake buffers 
as indicated in the column headings. Data generated from assays in the “Original” buffer combination was used for model estimations 
of Vmax. The dependence of the model calculations on the data from different buffer combinations used as input was probed using the 
“Test” buffer combinations. The mean 𝑉𝑚𝑎𝑥,𝑖  ± SEM for the four ”Test”  buffer combinations is 32.4 ± 2.7 for xB
0AT1 and 391.5 ± 5.2 
for xLAT4.  
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experimental data for the tested uptake buffers (Figs. 2.3 and 2.4). For example, in 
Na+free buffer, if the model calculations were correct, then only the Na+-indep xLAT4 
and not the Na+-dep B0AT1 could have contributed to total Leu uptake.  As we 
predicted, excess added Ala ± Trp did not inhibit Leu uptake relative to uptake in 
Na+free buffer alone (since neither AA is a substrate for LAT4) (Figs. 2.2 and 2.3C). 
There are several other Na+-indep xAAT species (LAT1, 2, 3) with reported mRNA 
expression in oocytes. Since Ala is a LAT2 substrate, and Trp is a substrate for LAT1 
and LAT2, if either AAT species were significantly active in  
 
 
Figure 2. 3.  L-leucine uptake by endogenous Xenopus laevis oocyte  
transporters. Three minute uptakes by non-injected (NI) oocytes of 10 – 1000 µM L-
leucine (Leu) in uptake buffers containing (+Na+) and without sodium (Na+free) were 
tested using radiolabeled amino acid (AA) tracers. In all panels uptake data (pmol/3 
min per oocyte) were normalized to uptake in 1 mM Leu, +Na+ uptake buffer for each 
batch of oocytes and experimental day. Panel (A) shows normalized Leu uptake rate 
data (expt) vs. the simultaneous fit (fit) for endogenous Leu uptake rates. Panel (B) 
shows model calculations (model) for contributions to uptake of 10 – 1000 µM Leu by 
various endogenous Xenopus laevis oocyte (xAAT) species. Model output was 
calculated based on the calculated xAAT 𝑉𝑚𝑎𝑥,i  and the reported 𝐾𝑚  for each xAAT 
ortholog (Table 2. 1). The 95% confidence limits for transporter activities 
are shown (dotted lines) bracketing the model predictions. Panels (C) and (D) show 
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the calculated Leu uptake rates in +Na+ and Na+ free uptake buffers containing excess 
competitive inhibitors. Panel (C) shows the concentration dependence (0 – 1000 µM 
Leu) of normalized cumulative uptake data by NI oocytes in Na+free uptake buffers 
containing 10 mM each of the following competitors: L-alanine (Ala) (Na+free+Ala), Ala 
and L-tryptophan (Trp) (Na+free +Ala +Trp), L-valine (Val) (Na+free +Val) vs. calculated 
cumulative endogenous uptake results for the respective uptake buffers. For uptakes 
in Na+free+Ala, and Na+free+Ala+Trp uptake buffers, the calculated values were 
virtually indistinguishable from the global fit for the Na+free data, therefore a single line 
was used for graphing all three data sets. Panel (D) shows the concentration 
dependence (0 – 1000 µM) of total Leu uptake rates in +Na+ uptake buffers containing 
10 mM each of the following competitors: Ala, Arg (+Na++Ala+Arg), 2-aminobicyclo-
(2,2,1)-heptane-2-carboxylic acid (BCH), (+Na++BCH), and BCH and Ala 
(+Na++BCH+Ala) (Fig. 2. 2). n = 6 – 8 ooyctes each experiment, for 3 independent 
experiments. The experimental data are shown as the mean ± SEM for the measured 
uptake rates and the calculated cumulative endogenous uptake rates were based on 
the previously calculated 𝑉𝑚𝑎𝑥  and reported 𝐾m  values for the kinetic components 
exhibited by each AAT species (Table 2. 1).  
oocytes, then addition of excess Ala or Trp would have competitively inhibited Leu 
uptake (Fig. 2. 2). Furthermore, our predicted decrease in total Leu uptake in the 
presence of added Val (a LAT4 substrate) was confirmed (Fig. 2. 3C).  
The cumulative Leu uptake rates by xAATs measured in +Na+ with 10 mM of the 
competitive substrates (1) +Ala+Arg,  (2) +BCH, or (3) +BCH+Ala vs. the calculated 
results is shown in Fig. 2. 3D. Briefly, Ala is a substrate for B0AT1 but not LAT4, while 
excess Arg does not compete for Leu uptake by either AAT species, and BCH 
competitively inhibits LAT4 but not B0AT1 (Fig. 2. 2). Therefore, if the model 
calculations were correct, we predicted (as observed) that the total Leu uptake from 
highest to lowest would be: +Na+ (100%) > Na++Ala+Arg (Ala inhibits only the lesser 
active xB0AT1) > Na++BCH (BCH inhibits the highly active xLAT4) > Na++BCH+Ala 
(inhibits both xB0AT1 and xLAT4 activity) (Fig. 2. 3D). Overall, total Leu uptake curves 
were accurately calculated for all tested uptake buffers, supporting the validity of the 
model output (Figs. 2.2 and 2.3D, E). 
Calculating the relative activity exogenously expressed transporters   
The utility of the model for calculating the activity of heterologously expressed AATs 
distinct from xAATs was tested for exogenously expressed hATB0,+. The uptake 
measured from non-injected (NI) and hATB0,+ injected oocytes was compared with 
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calculated uptake rates (Fig. 2. 4A). Using the total uptake measured from hATB0,+ 
injected oocytes (NI+hATB0,+) for two Leu concentrations (10 and 1000 µM), the 
maximum normalized transport rate for exogenously expressed hATB0,+ transporters 
( 𝑉𝑚𝑎𝑥,hATB0,+ ) was calculated as 139.7 ± 26.9 (equation (9), Fig. 2. 4A). This value was 
used in the MM equation together with the reported  𝐾𝑚,hATB0,+    
value (Table 2. 1) to 
calculate the rate of uptake by hATB0,+  transporters from 0 – 3000 µM Leu (Fig. 2. 
4B).  The hATB0,+ transport rate was calculated to plateau at ≈ 100 µM as expected 
from the high affinity of hATB0,+ for Leu (Table 2. 1, Fig. 2. 4B). Furthermore, with 
increased Leu concentrations the total uptake in both hATB0,+ expressing and NI 
oocytes was increasingly due to activity of xLAT4 (and to a lesser extent xB0AT1) 
transporters (Figs. 2.3C and 2.4B). In hATB0,+ expressing oocytes, the relative 
contribution of xLAT4 transporters to total Leu uptake rate was calculated to increase 
from less than 20% of hATB0,+ activity at 100 µM to approximately 40% higher than 
that of hATB0,+ at 3 mM Leu (Fig. 2. 4B).  
 
Figure 2. 4. L-leucine and L-phenylalanine uptake by endogenous Xenopus 
laevis oocyte and exogenously expressed human sodium-dependent symporter 
SLC6A14/ATB0,+ and sodium-independent uniporter SLC43A2/LAT4 
transporters. L-Leucine (Leu) uptake rates (pmol/3 min per oocyte) from non-injected 
(NI) and oocytes expressing human ATB0,+ (hATB0,+) were compared with model 
calculations. Measured uptake data (pmol/10 min per oocyte) for each batch of oocytes 
and experimental day was normalized to uptake rates by NI oocytes in 1 mM Leu, +Na+ 
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uptake buffer. Panel (A) shows measured Leu (10 – 3000 µM) uptake rates for NI 
oocytes (NI, expt), and for oocytes expressing hATB0,+ without subtraction of NI uptake 
data (NI+hATB0,+, expt) vs. the calculated model outputs for the respective oocytes 
(NI, model; and NI+ATB0+, model). Panel (B) shows experimental data for total Leu (0 
– 3000 uM) uptake rates by hATB0,+ expressing oocytes with subtraction of NI oocyte 
uptake rates (+hATB0,+, expt) vs. calculated Leu uptake by endogenous Xenopus 
laevis oocyte Leu transporters (xB0AT1, model; and xLAT4, model) and exogenous 
hATB0,+ transporters (+hATB0,+, model ). n = 6 − 8 oocytes per experiment for 7 
independent experiments. Panels (C) and (D) show  L-phenylalanine (Phe) uptake data 
(pmol/10min per oocyte) in Na+containing uptake buffer vs. model calculations for 
endogenous Phe transporters (xB0AT1, xLAT4, xTAT1) and human LAT4 (hLAT4) 
transporters. Experimental uptake (pmol/10 min per oocyte) for all oocytes was 
normalized to uptake in 10 mM Phe, Na+ containing- uptake buffer (Na+). Panel (C) 
shows normalized total Phe uptake rates by NI oocytes (NI, expt) vs. oocytes with 
expressed hLAT4 without subtraction of NI oocyte uptake (NI+hLAT4, expt) vs. 
calculated data for the respective oocyte uptakes (NI, model; and NI+hLAT4, model). 
Panel (D) shows the normalized data for 0 – 10 mM Phe uptake rates by oocytes 
exogenously expressing hLAT4 with subtraction of NI uptake (hLAT4, expt) vs. model 
calculations for hLAT4 (hLAT4, model) and xAAT Phe transporters (xB0AT1, model; 
xLAT4, model; and xTAT1, model). n = 6 − 8 oocytes each experiment for 4 
independent experiments. For panels (B) and (D), 95% confidence limits for predicted 
transporter activities are shown (dotted lines) bracketing the model predictions for 
each AAT activity. 
 
Prediction of L-phenylalanine transport from L-leucine data 
The versatility of the model was further probed by calculating the uptake of a second 
AA (Phe) based on results for Leu. Specifically, experimental data for Phe uptake by 
NI and hLAT4 expressing oocytes were compared with calculations of Phe uptake 
based on the xAAT expression previously determined from Leu data. Six of the 
potentially expressed xAAT species transport both Leu and Phe (xATB0,+, xB0AT1, 
xLAT1, xLAT2, xLAT3, xLAT4). Phe uptake rates by xAAT species were calculated 
using the reported Phe 𝑉𝑚𝑎𝑥   values for the respective exogenously expressed 
orthologs (Table 2. 1) and the previously calculated Leu 𝑉𝑚𝑎𝑥  values for the xAAT 
species (Table 2. 2). As expected, in NI oocytes only activity of xB0AT1 and xLAT4 
transporters contributed to Phe uptake. In addition, oocytes express mRNA (Xenbase) 
for the TAT1 transporter species, which transports Phe but not Leu. Using NI uptake 
measured at 2 Phe concentrations (1000 and 10000 µM), the maximum transport rate 
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for xTAT1 transporters was calculated (equation (4)). Relative Phe 𝑉𝑚𝑎𝑥   for xB
0AT1, 
xLAT4, and xTAT1 transporters (estimated as 2.39±0.39, 14.34±0.34 and 408±9.5, 
respectively) were used together with the corresponding reported Phe 𝐾𝑚 values 
(Table 2. 1) in the MM equation to calculate the uptake rates from 0 – 10000 µM Phe 
(Fig. 2. 4C). These results indicated that the activity of xTAT1 transporters 
predominated at all Phe concentrations. The 𝑉𝑚𝑎𝑥   of xTAT1 for Phe transport was 
approximately 28 times that of xLAT4 and 170 times that of xB0AT1 (Fig. 2. 4D). The 
𝑉𝑚𝑎𝑥  of xLAT4 for Phe transport was approximately 6 times that of xB
0AT1. 
Furthermore, for both xLAT4 and xB0AT1 the calculated 𝑉𝑚𝑎𝑥  for Phe transport was 
approximately 13X and 27X lower than for Leu, respectively (Figs. 2.3B and 4D). The 
calculated cumulative uptake rates of Phe by xAATs was found to compare well with 
the data measured from NI oocytes (Fig. 2. 4C,D).  
The hLAT4 to xLAT4 expression ratio was estimated from uptake data for 2 Phe 
concentrations (1000 µM and 10,000 µM) as 18.56 ± 0.44. The 𝑉𝑚𝑎𝑥,hLAT4  for Phe 
transport by hLAT4 was estimated (see Methods) and used with reported hLAT4 𝐾𝑚 
for Phe (Table 2. 1) to calculate uptake from 0 – 10 mM Phe. The model predictions 
for cumulative uptake of Phe in both NI and hLAT4 expressing oocytes were found to 
be in good agreement with the experimental data. For Phe, xTAT1 transporters, in 
addition to xLAT4 transporters, were calculated to have contributed significantly to 
uptake by NI oocytes. Overall, these findings support the conclusion that model 
calculations for relative AAT activity based on Leu data were generalizable to describe 
the transport of Phe and potentially other substrates (Fig. 2. 4C,D).  
Discussion 
Using a systems biology strategy, we developed an accurate, robust, and versatile 
method to calculate the relative contributions of different SLC species in the total 
cellular transport of a given substrate (Fig. 2. 1). Here we demonstrated this approach 
as applied to the characterization of Leu and Phe AAT activities in X. laevis oocytes 
(Figs. 2.3 and 2.4). Using our method the transport rates in diverse uptake buffers by 
endogenous and exogenous transporters were accurately calculated as verified by the 
measured data.  
Quantification of relative endogenous transporter activities  
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It has long been hypothesized that the AA transport systems B0,+, L, ASC, asc, b0,+ are 
active in X. laevis oocytes [72]. In this study the activities of potentially expressed 
endogenous oocyte Leu and Phe AAT species (based on Xenbase mRNA data) were 
calculated. All of the xAAT species proposed by Van Winkle and co-workers to be 
expressed were reported by Xenbase to have some level of mRNA expression in 
unfertilized oocytes. However, since many factors influence protein expression and 
activity, no conclusions can be drawn about specific xAAT protein activities on the 
basis of mRNA expression alone. Indeed, based on model output we propose that only 
two xAAT species, the low affinity Na+-indep uniporter xLAT4, and the low affinity Na+-
dep symporter xB0AT1 contribute to endogenous Leu uptake (Fig. 2. 3A,B). Two kinetic 
components for transport by LAT4 have been reported [45]. From our calculations, only 
the xLAT4 low affinity component contributed to transport under all assay conditions.  
Model parameters 
There is a very little information about Xenopus AAT kinetics, therefore, the substrate 
affinities of human or mouse orthologs were used for modeling (Table 2. 1 and Fig. 2. 
2). Given that many AATs are essential and highly evolutionarily conserved, 
differences in ortholog kinetics that might affect model output, may be relatively minor 
[73, 74]. Furthermore, physiological parameters such as blood AA levels support the 
idea that Xenopus transporters likely evolved in similar environments as mammalian 
AATs. For example, Leu concentration in Xenopus plasma was reported as 150 µM[75] 
which is consistent with values reported for humans[2] and mice[76]. Additionally, in 
vitro studies using Xenopus intestines demonstrate similar drug permeabilities as 
human intestines indicating frog transporter kinetic and substrate specificities mimic 
human transporter activity[77].Salmon SLC6A19/B0AT1 expressed in Xenopus 
oocytes was found to have similar kinetics as mouse B0AT1[78]. Additionally, Xenopus 
Glutamate ionotrophic transporters were found to function, with only minor differences, 
kinetically like their rat homologs[79]. Taken together these various data support the 
hypothesis that Xenopus transporters may likely display similar kinetic parameters as 
their mammalian counterparts.  
However, if Xenopus AAT 𝑉𝑚𝑎𝑥   or 𝐾𝑚  values differ significantly from reported literature 
values for mammalian orthologs, then the calculated activity of xAATs would be 
correspondingly impacted. Substrate 𝐾𝑚 determines the fractional occupancy of a 
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transporter for a given substrate concentration, and therefore, calculations for AAT 
activity. In particular regarding calculations for xLAT3 and xLAT4 transporter activity, it 
is important to note that the best fit (lowest MRE) results when the xAAT with the lowest 
affinity is active. Given the mammalian Km values this is assumed to be xLAT4. Since 
the Leu Km values for xLAT3 and xLAT4 are not definitively known, it is possible that 
that either xLAT4 or xLAT3 is the predominant endogenous Leu transporter. However, 
the minimal competition of Leu uptake by 10 mM L-valine (Val) in Na+free buffer is 
more consistent with xLAT4 than xLAT3 activity; assuming that like their mammalian 
orthologs xLAT4 has an approximately 20 times lower affinity for Val than xLAT3 (Table 
2.1, Figs.2.2, and 2.3C, D). 
In general while SLC orthologs are well-conserved structurally and functionally, for 
some transporters interspecies kinetic differences do exist [80]. Furthermore, while the 
model calculates the best fit to the overall Leu uptake data as resulting from the 
predominant activity of xLAT4 and xB0AT1, it is possible that other transporters may 
have minimal activity. Nevertheless, the strong congruence between model 
calculations and independently generated experimental data for endogenous and 
exogenous AATs supports the validity of the model output for X. laevis Leu and Phe 
transporters (Figs. 2.3 and 2.4).  
Versatility of the method 
Although, we based our calculations on data generated from Leu concentration-
dependence uptake assays carried out in ± Na+ buffers, calculations using other buffer 
combinations reached similar values (SEM < 10% of the mean). This result 
demonstrates the versatility of the approach for application to a variety of assay 
conditions (Table 2. 2). Additionally, our conclusions regarding the activities and 
expression of transporters are supported by the close concurrence of calculated 
responses with measured data for different stimuli. Model output was compared with 
uptake rates in the presence of added excess competitive substrates (Fig. 2. 3C, D), 
as well as, exogenously expressed human transporters (Fig. 2. 4). Furthermore, the 
model, which was initially constructed for calculating Leu transporter activities, was 
shown to be extrapolatable to report activity of Phe transporters (Fig. 2. 4C,D).  
Applications  
 38 
 
 
Our systems biology approach provides a method to quantitatively calculate the 
aggregate cellular transport and relative contributions of specific transporter activities 
for given substrates in different assay conditions. Some AA, peptide, and other SLC 
transporters have been shown to carry a broad variety of drugs (e.g., levodopa, 
antibiotics, ACE inhibitors etc) [81]. Thus, our approach could potentially be helpful in 
modeling SLC transporter responses to drugs even when the protein expression of 
candidate transporters is not known. For example, the relative contributions of specific 
transporters in different cell types for a given drug or combination of drugs could be 
quantified. Thereby, potential strategies could be assessed for increasing treatment 
efficacy by modulating drug influx to targeted tissues or tumors. Additionally, 
therapeutics could be evaluated to decrease unwanted side effects by, for example, 
increased exclusion and/or efflux of drugs from spurious or deleterious targets. 
Furthermore, this framework is not limited to SLC transporters and theoretically could 
be applied to a variety of enzymatic systems. Taken together, the availability of a 
platform that provides the simultaneous calculation of the contributions of specific 
enzymes in an enzymatic system and their overall responses to new stimuli promises 
to be an asset for basic and applied research. 
Summary 
We established an adaptable systems biology approach to characterize the 
contributions of specific enzyme species to overall catalytic activity based on limited 
experimental input. Using this approach, we could accurately calculate responses to 
new stimuli. In this study, we applied the strategy to characterize Leu and Phe SLC 
AAT species using the X. leavis oocyte in vitro cell model. However, given the 
appropriate assay conditions, this approach is applicable to many other enzymes, 
substrates, and/or cellular systems. 
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Supplementary Figure 2. 1. Time course of L-leucine uptake by non-injected 
Xenopus laevis oocytes. L-leucine uptake rates by non-injected oocytes was tested 
by radiolabeled amino acid tracer experiments at ten time points (1, 2, 3, 4, 8, 12, 13, 
15, 21, 25 minutes) with 1 mM unlabeled L-leucine in 100mM sodium containing uptake 
buffer (+Na+) The linear fit to the uptake data (pmole per oocyte) for 1-8 minutes was 
calculated and the data graph prepared using GraphPad Prism 5.0 (GraphPad 
Software, San Diego, CA) (n = 6 − 8 oocytes per time point for one experiment).  
 
Chapter 3   Functional polarity of microvascular brain endothelial 
cells supported by neurovascular unit computational model of large 
neutral amino acid homeostasis 
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Abstract 
The homeostatic regulation of large neutral amino acid (LNAA) concentration in the brain 
interstitial fluid (ISF) is essential for proper brain function. LNAA passage into the brain is 
primarily mediated by the complex and dynamic interactions between various solute carrier 
(SLC) transporters expressed in the neurovascular unit (NVU), among which SLC7A5/LAT1 is 
considered to be the major contributor in microvascular brain endothelial cells (MBEC). The 
LAT1-mediated trans-endothelial transport of LNAAs, however, could not be characterized 
precisely by available in vitro and in vivo standard methods so far. To circumvent these 
limitations, we have incorporated published in vivo data of rat brain into a robust computational 
model of NVU-LNAA homeostasis, allowing us to evaluate hypotheses concerning LAT1-
mediated trans-endothelial transport of LNAAs across the blood brain barrier (BBB). We show 
that accounting for functional polarity of MBECs with either asymmetric LAT1 distribution 
between membranes and/or intrinsic LAT1 asymmetry with low intraendothelial binding affinity 
is required to reproduce the experimentally measured brain ISF response to intraperitoneal 
(IP) L-tyrosine and L-phenylalanine injection. On the basis of these findings, we have also 
investigated the effect of IP administrated L-tyrosine and L-phenylalanine on the dynamics of 
LNAAs in MBECs, astrocytes and neurons. Finally, the computational model was shown to 
explain the trans-stimulation of LNAA uptake across the BBB observed upon ISF perfusion 
with a competitive LAT1 inhibitor. 
Keywords: blood brain barrier, neurovascular unit, amino acid transporter, large neutral 
amino acid, SLC7A5/LAT1 
 
 
Introduction 
The blood-brain barrier (BBB) is a truly dynamic interface separating the brain from the 
bloodstream. It is formed by highly specialized microvascular brain endothelial cells (MBECs) 
connected by tight junctions forming brain capillaries. The BBB endothelium together with the 
astrocytes and neurons are the fundamental elements of the neurovascular unit (NVU) system.  
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Numerous solutes move across the NVU cell membranes with various transport mechanisms. 
While small lipophilic molecules can diffuse, larger and hydrophilic solutes, such as amino 
acids (AAs), need the assistance of specialized carrier proteins to cross the membrane, for 
instance amino acid transporters (AATs) [82]. NVU-AATs are expressed at both luminal and 
abluminal membranes of the MBECs, as well as on astrocytes and neurons. The NVU-AATs 
mediate the transfer of particular amino acids with different transport mechanisms: antiporters, 
for example, exchange some AAs for others across the membrane, while symporters 
cotransport AAs together with ions along the ions’ electrochemical gradient [83]. Taken 
together, different classes of NVU-AATs constitute an integrated dynamic system controlling 
the homeostasis of AAs such as large neutral amino acids (LNAAs: L-tyrosine, L-leucine, L-
isoleucine, L-phenylalanine, L-histidine, L-valine, L-tryptophan and L-methionine) in the brain 
interstitial fluid (ISF). The homeostasis maintenance of LNAA concentrations, which have been 
shown to be asymmetrically distributed in the plasma and individual NVU compartments [76, 
84, 85], is of particular importance due to their crucial role in the central nervous system (CNS), 
for instance as precursors of key neurotransmitters such as Dopamine, Serotonin, and 
Histamine.    
Figure 2. 1 illustrates a simplified model of the adult rat NVU that includes the dominant LNAA 
transporter of each cell membrane. The NVU-LNAAs have been shown to be transported 
mainly, but not exclusively, by SLC7A5 (LAT1), SLC6A15 (B0AT2) and/or SLC7A8 (LAT2). 
LAT1 associated with the accessory subunit 4F2hc (SLC3A2) functions as a Na+-independent 
antiporter and plays a dominant role at the luminal and abluminal membranes of the MBECs 
[24-26]. B0AT2 is a Na+-dependent symporter which has been shown to be the dominant 
uptake pathway for LNAAs in neurons [30-32]. A number of studies have shown that the Na+-
independent antiporter LAT2 also associated with 4F2hc is the major mediator of LNAA 
transport in primary astrocytes [27-29]. While it has to be mentioned that comparably high 
LAT1 mRNA levels have been detected by Zhang Y, et al. [86] in freshly isolated astrocytes, 
the functional contribution of this transporter remains unclear [29]. In vivo assays and in vitro 
measurements carried out on freshly isolated cells have shown that the expression of other 
AATs, such as y+LAT2/SLC7A6 (SLC7A6) and ASCT2/SLC1A5 (SLC1A5), is very low in adult 
brain compared to the aforementioned AATs [87-89]. Therefore, based on the available 
evidence in the literature, we consider LAT1, LAT2, and B0AT2 to be the predominant LNAA 
transporters in MBECs, astrocytes and neurons, respectively. Taken together, these 
transporters co-operate as a highly complex and integrated dynamic system to predominantly 
control the homeostasis of LNAAs in the brain ISF. For example, LNAAs in the brain ISF can 
be taken up by B0AT2 localized in neurons, and/or they can be exchanged with other LNAAs 
of astrocytes (mediated by LAT2) and/or be transported back into MBECs and eventually into 
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the bloodstream via LAT1 expressed at the abluminal and luminal membranes of the MBECs 
(Fig. 3. 1).   
 
 
Figure 3 1.  Diagram of the dominant LNAA transporters expressed in cells of the 
neurovascular unit (NVU). The diagram represents the major compartments of the brain with 
the dominant NVU carrier-mediated LNAA transport pathways from brain capillary plasma 
(input) across blood brain barrier (BBB) microvascular endothelial cells (MVEC) into the 
interstitial fluid (ISF) and from there into astrocytes and neurons. The abbreviations used for 
the NVU-SLC transporters are LAT1 (SLC7A5) and LAT2 (SLC7A8), both Na+-independent 
large neutral amino acid antiporters, and B0AT2 (SLC6A15), a Na+-dependent large neutral 
amino acid symporter. The arrows indicate the transmembrane pathways of LNAAs via these 
transporters into and out of the NVU cells. TL and CL represent test and competing large 
neutral amino acids, respectively. 
 
Among the aforementioned dominant transporters, LAT1 is the central element of the NVU that 
is involved in the regulation of LNAA homeostasis in the brain ISF. However, despite its 
importance, its bi-directional kinetic behavior across the BBB has not been characterized yet. 
We have previously investigated the bi-directional kinetics of LAT1 using the Xenopus laevis 
oocyte expression system, and observed strongly asymmetric bi-directional kinetics (high 
extra-cellular versus low intra-cellular binding affinity) [26, 33], a finding that has recently been 
confirmed by reconstitution experiments in proteoliposomes [90]. However, it remains unclear 
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whether this bi-directional asymmetry is dependent on the cell type, and whether it may be 
influenced by the regulatory/modulatory function of gene products absent in Xenopus laevis 
oocytes and possibly present in other cell types such as MBECs [26, 33]. In vivo tracking of 
LNAAs from MBECs toward blood plasma and ISF could provide information on the bi-
directional kinetic behavior of MBEC LAT1. However, there is currently no suitable in vivo 
technique available to achieve this. While bi-directional uptake and efflux assays using in vitro 
models of MBECs could be used, they may not reflect the in vivo situation because of the high 
sensitivity of the expression level of AATs to culture conditions [34]. In addition to the unclarity 
regarding the bi-directional kinetics of LAT1 in MBECs, the abluminal to luminal expression 
ratio of LAT1 at the BBB is not well known yet. Only a study carried out in isolated vesicles has 
characterized the relative expression of LAT1 at the BBB [91], but this approach may not reflect 
the situation in vivo [35]. Taken together, for the above mentioned reasons, the bi-directional 
kinetic behavior of LAT1 in MBECs as well as its distribution pattern at the luminal and 
abluminal membranes of the BBB could so far not be addressed satisfactorily. 
To circumvent these limitations, we have developed a robust computational model of LNAA 
homeostasis in the NVU based on a mathematical description of the nonlinear mechanistic 
kinetics of the dominant individual NVU-LNAA transporters in conjunction with published in 
vivo LNAA microdialysis (MD) measurements performed in the rat brain ISF upon 
intraperitoneal administration of L-tyrosine and L-phenylalanine [92, 93]. This has allowed us 
to explore potential asymmetries of LAT1 bi-directional kinetics and expression in MBECs. Our 
computations support the hypothesis that MBECs exhibit a functional polarity for LNAAs due 
to an asymmetry in either bi-directional kinetics and/or expression of LAT1 in MBECs. In 
addition, we have employed our model to capture changes in LNAA levels in MBEC, 
astrocytes, and neurons upon perturbations of plasma LNAA concentrations. Finally, we 
employed the computational model to explain the trans-stimulation of LNAAs upon ISF 
perfusion of MBEC LAT1 competitive inhibitor.  
 
Methods 
Transport model 
The NVU is represented by four interacting compartments for MBEC, ISF, astrocytes, and 
neurons, each with a homogeneous mixture of LNAAs. The plasma conditions are prescribed 
as dynamic inputs to the NVU (Fig. 3. 1). Carrier-mediated transport of LNAAs between the 
compartments is represented by fluxes dominantly mediated by AATs located at the interface 
between compartments [21, 22, 94]. Following these modeling assumptions, temporal changes 
in the test LNAA (TL) concentration within the individual NVU compartments are given by     
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 d[TL]
MBEC
dt
=
1
VMBEC
 (f LAT1,lum
P→MBEC − f LAT1,abl
MBEC→ISF) ,  
                  
1 
 d[TL]
ISF
dt
=
1
VISF
 (f LAT1,abl
MBEC→ISF − f LAT2
ISF→Ast − f B0AT2
ISF→Neu) ,  
               
2 
  d[TL]
Neu
dt
=
f B0AT2
ISF→Neu
VNeu
 ,  
            
3 
  d[TL]
Ast
dt
=
f LAT2
ISF→Ast
VAst
 ,  
             
4 
where  [TL]i and Vi represent the concentration of the test LNAA in the compartment i and the 
volume of that compartment, respectively. The carrier-mediated flux of test LNAA from 
compartment i to compartment j is denoted with f AAT
i→j , and P, MBEC, ISF, Neu, and Ast refer to 
plasma, microvascular brain endothelial cell, brain interstitial fluid, neuron and astrocyte, 
respectively. Subscript lum and abl refer to the luminal and abluminal membranes of the 
MBEC, respectively.  
The fluxes of LNAAs between NVU compartments depend on the mechanism of the individual 
transporters and their dependence on (or independence of) sodium ions. LAT1 and LAT2 are 
sodium independent antiporters, while B0AT2 functions as a sodium dependent symporter [26, 
32]. The fluxes mediated by these transporters are given by [21, 22, 94, 95]   
         f LAT1,lum
P→MBEC =
2Vmax,LAT1,lum,TL ([TL]
P[CL]MBEC−[TL]MBEC[CL]P)
Km,LAT1,TL
P([TL+CL]P+[TL+CL]MBEC) + (
Km,LAT1,TL
P
Km,LAT1,TL
MBEC+1) ([TL+CL]
P [TL+CL]MBEC)
 ,       5 
         f LAT1,abl
MBEC→ISF =
2Vmax,LAT1,abl,TL([TL]
MBEC[CL]ISF−[TL]ISF[CL]MBEC)
Km,LAT1,TL
MBEC([TL+CL]MBEC+[TL+CL]ISF)+(
Km,LAT1,TL
MBEC
Km,LAT1,TL
ISF +1)([TL+CL]
MBEC [TL+CL]ISF)
 ,                                         6 
  f LAT2
ISF→Ast =
2Vmax,LAT2,TL ([TL]
ISF[CL]Ast − [TL]Ast[CL]ISF)
Km,LAT2,TL
ISF([TL + CL]ISF + [TL + CL]Ast) + (
Km,LAT2,TL
ISF
Km,LAT2,TL
Ast + 1) ([TL + CL]
ISF [TL + CL]Ast)
,       7 
 f B0AT2
ISF→Neu =
2Vmax,B0AT2,TL
D
(𝜀𝜀′[Na]ISF[Na]Neu ([TL]ISF[CL]Neu − [TL]Neu[CL]ISF
+ 𝜀′ [TL]ISF[Na]ISF Km,B0AT2,CL
Neu Km,B0AT2,Na
Neu
− 𝜀 [TL]Neu[Na]Neu  Km,B0AT2,TL
ISFKm,Na
ISF), 
D = [Na]ISF[Na]Neu(𝜀′ [TL + CL]ISF( [TL + CL]Neu + Km,CL
Neu) + 𝜀 [TL + CL]Neu( [TL + CL]ISF +
Km,B0AT2,TL
ISF)) + [Na]ISFKm,B0AT2,CL
Neu Km,B0AT2,Na
Neu [TL + CL]ISF(𝜀′ + 1) +
[Na]Neu Km,B0AT2,TL
ISF Km,B0AT2,Na
ISF [TL + CL]Neu (𝜀 + 1) +
Km,B0AT2,TL
ISFKm,B0AT2,CL
Neu([Na]ISF Km,B0AT2,Na
Neu    + [Na]Neu Km,B0AT2,Na
ISF) +
2  Km,B0AT2,TL
ISF Km,B0AT2,CL
Neu  Km,B0AT2,Na
ISF Km,B0AT2,Na
Neu, 
   𝜀 =𝑒(
β z F
R T
 Δψ) and 𝜀′ = 𝑒(
(β−1)z F
R T
 Δψ  ), 
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Where [CL]i represents the concentration in compartment i of LNAAs competing with the test 
LNAA, and Vmax,AAT,TL and  Vmax,AAT,CL are the maximum transport rate of the AATs for the test 
and competing LNAA (competitive inhibitors of test LNAA), respectively. In Eq. (8), 𝜀 and 𝜀′ are 
the electrical potential-induced biases for forward and backward transport rates, respectively, 
and Δψ, β, F, z, R, and T represent potential difference, electrical bias constant, Faraday 
constant, sodium charge, gas constant and absolute temperature, respectively [22, 94, 95]. 
Km,AAT,TL
i and Km,AAT,CL
i are, respectively, the AAT apparent Michaelis-Menten binding 
constants for the test and competing LNAAs in the presence of competitors. They are 
determined by [25, 96] 
Km,AAT,TL
i = Km,abs,AAT,TL
i (1 +
[CL]i
Km,abs,AAT,CL
i), 
Km,AAT,CL
i = Km,abs,AAT,CL
i (1 +
[TL]i
Km,abs,AAT,TL
i), 
  9 
where Km,abs,AAT,TL
i and Km,abs,AAT,CL
i are, respectively, the AATs absolute Michaelis-Menten 
binding constants for test and competing LNAAs in the absence of competitors [25, 96]. For 
simplicity, the competing LNAAs are treated as a single-entity component, representing the 
overall concentration of the mixture of individual competing LNAAs (Fig. 3. 1). The maximum 
transport rate and the overall absolute Michaelis-Menten binding constant for the competing 
LNAA,  Vmax,AAT,CL and Km,abs,AAT,CL
i, respectively, are given by [97, 98]:   
 Vmax,AAT,CL =
∑ (
 Vmax,AAT,CLk [CLk]
Km,abs,AAT,CLk
)nk=1
∑ (
 [CLk]
Km,abs,AAT,CLk
)nk=1
, 
 Km,abs,AAT,CL
𝑖 =
∑  [CLk] 
n
j=1
∑ (
 [CLk]
Km,abs,AAT,CLk
) nj=1
, 
          10 
where [CLk] and Km,abs,AAT,CLk represent, respectively, the concentration and the absolute 
Michaelis-Menten binding constant of the individual competing LNAAs within the considered 
mixture (see Suppl. Table 3. 1), and where n is the total number of individual competing 
LNAAs.  
The MBEC LAT1 bi-directional kinetics are modeled as 
 Km,abs,LAT1
MBEC =   RKLAT1  Km,abs,LAT1
P(ISF), 
11 
where  RKLAT1 is the LAT1 bi-directional kinetic constant, which represents the absolute 
Michaelis-Menten binding constant for LAT1 in MBECs relative to the corresponding value at 
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the outside of MBECs in the ISF and in plasma. The LAT1 expression ratio in MBECs is 
modeled as 
Vmax,LAT1,abl =   RELAT1 Vmax,LAT1,lum, 12 
where  RELAT1 represents the relative ratio for the maximum transport rate of LAT1 at the 
abluminal membrane of the MBECs to the corresponding value at the luminal membrane. Eqs. 
(5-12) and Eqs. (1-4) can be combined to describe the intercompartmental rate of change in 
the concentration of the test LNAAs,(d[TL]
i
dt
), as a system of nonlinear ordinary differential 
equations of the following general form:  
   
 d[TL]i
dt
= function ([TL]i, [CL]i, Vi , Km,AAT,TL
i,  Km,AAT,CL
i, Vmax,AAT,TL, Vmax,AAT,CL, RKLAT1, RELAT1)  
 
13 
The intra-compartmental concentration change rate of the competing LNAAs (d[CL]
i
dt
) can be 
formulated similarly. Values for kinetic parameters of individual AATs (Km,abs,AAT,TL
i, 
 Km,abs,AAT,CL
i, Vmax,AAT,TL and Vmax,AAT,CL) and volumes of compartments (Vi) used in Eqs. (1-
13) are listed in Table 3. 1.  
Model initialization and numerical model 
To capture the responses of individual NVU compartments (MBEC, ISF, astrocyte, and 
neuron) to perturbations in plasma LNAA concentration, the baseline (pre-stimulus or pre-
injection) state of the system needs to be determined. To this end, we first obtain the steady-
state solution of Eq. 13 ( d[TL]
i
dt
 = d[CL]
i
dt
= 0 ) by prescribing constant plasma concentrations of 
LNAAs as NVU system input (Fig. 3.1 and Suppl. Table 3. 2) and solving the resulting system 
of equations whose unknowns are the baseline LNAA concentrations in the individual 
compartments. To do so, we are required to initialize the LNAA concentrations in individual 
NVU compartments. The LNAA concentrations in the ISF, astrocytes, and neurons are 
initialized according to baseline values reported in the literature ([TL]b
i  and [CL]b
i ) (Suppl. Table 
3. 2). Such information is not available for MBECs, however. Therefore, we initialize the 
corresponding LNAA concentration based on a parametric study obtained with random values 
of the initial baseline concentration (Suppl. Table 3. 2). It has to be noted that once the LNAA 
concentrations in the different compartments have been prescribed, the solution of the steady-
state problem is constrained in the total amount of LNAAs in the NVU. We examined whether 
this amount reflects in vivo conditions by extrapolating the calculated compartmental LNAA 
concentrations to the brain as a whole and comparing these values to experimental results 
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reported in [85, 99] , finding very good agreement (Suppl. Table 3. 2). Once the baseline or 
pre-stimulus state of the NVU system is determined, we calculate the post-stimulus state of 
the NVU in response to perturbations of LNAA concentrations in the plasma.  
All amino acid transport models were implemented in Matlab (R2015a). To calculate the 
concentration of LNAAs in the individual NVU compartments (pre- and post-stimulus states), 
we performed the time integration of Eq. 13 using the ode23s function (Bogacki–Shampine 
method) [100, 101].  The source code from Panitchob et al [94] has been used as a starting 
point for our implementation.  
Results 
Computational model combined with in vivo brain ISF measurements support a 
functional polarity of MBECs 
To discriminate, using our new computational model of the NVU, the hypothesized effects of 
asymmetry on bi-directional kinetics and expression of LAT1 in MBECs (see Introduction), we 
first searched the literature for kinetic parameters of LNAA transporters of the individual NVU 
compartments (Table 3. 1). Most carefully measured kinetic parameters of transport at the 
endothelial barrier reported by Smith et al.[25] were obtained by using in situ brain perfusion 
with short uptake times and thus likely represent the kinetics of the first step of LNAAs transport 
that is into MBECs across their luminal membrane [76, 92, 93, 102] and are thus not 
representative of steady-state trans-MBEC transport. Using these kinetic parameters, we first 
considered the bidirectional kinetics of LAT1 to be symmetric in MBECs (RKLAT1=1) and also 
assumed LAT1 to be symmetrically expressed at the luminal and abluminal membranes of 
MBECs (RELAT1=1). Under these assumptions of symmetry, we compared the output of our 
computational model with in vivo measurements made by Bongiovanni et al.[92]. In their study, 
they had increased the plasma level of L-tyrosine (test LNAA) by intraperitoneal (IP) injection 
in awake rats and simultaneously measured the post-stimulus response in the brain ISF by 
microdialysis. Using their measured plasma-stimulus profiles of the test LNAA L-tyrosine 
([TL]P) and of the L-tyrosine competing LNAAs (competitive inhibitors) ([CL]P) as input to the 
model (Fig. 3. 2A, results reported as a percentage of baseline), we calculated the 
corresponding post-stimulus responses in the brain ISF and found a significant mismatch 
between the measured and our calculated results which showed a larger excursion due to a 
much faster transport rate across MBECs (see results of statistical analysis in Fig. 3. 2B and 
Suppl. Table 3. 4).  
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Figure 3 2. Plasma concentration and corresponding brain ISF concentration response 
after intraperitoneal injection of L-tyrosine and L-phenylalanine. Panel (A) shows the 
plasma concentration of L-tyrosine (TL) and L-tyrosine competing LNAAs (CL) after 
intraperitoneal administration of 200 mg/kg L-tyrosine as measured by Bongiovanni et al. [92] 
and used as input for the model calculation. Panels (B) and (C) show the experimental data 
for the L-tyrosine (Tyr) post-stimulus response in the brain ISF, measured in the prefrontal 
cortex (PFC). Panel (B) shows the model calculations for various ratios of the bi-directional 
kinetic constant of MBEC LAT1 ( RKLAT1, Eq.11) with symmetric distribution of LAT1 at both 
luminal and abluminal membranes of the BBB ( RELAT1 = 1). Panel (C) shows the model 
calculations for various abluminal to luminal expression distribution ratios of LAT1 ( RELAT1, 
Eq.12) with symmetric bi-directional kinetics (RKLAT1 = 1). The model results and experimental 
data are represented as percent of the baseline value. In panel (A), the plasma baseline value 
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for L-tyrosine and L-tyrosine competing LNAAs (constant input) are 112 and 535 µM [84, 92], 
respectively. In panels (B) and (C), the ISF baseline value for L-tyrosine is 1.0 and 1.1 µM 
(Suppl. Table 3. 2), respectively. Each experimental data point represents the mean ± SD for 
three (plasma) and four to eight (ISF) animals [92]. In panel (A), the CL refers to a mixture of 
L-tyrosine competing LNAAs (L-leucine, L-isoleucine, L-phenylalanine, L-tryptophan, L-valine, 
L-histidine and L-methionine). The error bars associated with model calculations indicate 
standard deviation with respect to concentrations obtained with the nominal model parameter 
set (see Methods). Panel (D) shows the measured plasma concentration of L-phenylalanine 
(TL) and L-phenylalanine competing LNAAs (CL) after intraperitoneal administration of 200 
mg/kg L-phenylalanine as measured by [93, 103]. Panels (E) and (F) show the experimental 
data for the L-phenylalanine (Phe) post-stimulus response in the brain ISF, measured in the 
prefrontal cortex (PFC) versus model calculations for different ratios for the bi-directional 
kinetic constant of MBEC LAT1 ( RKLAT1, Eq.11), assuming symmetric distribution for LAT1 at 
luminal and abluminal membranes of the BBB ( RELAT1 = 1) and the model calculations for 
various abluminal to luminal expression distribution ratios of LAT1 ( RELAT1, Eq.12), assuming 
symmetric bi-directional kinetics of MBEC LAT1 (RKLAT1 = 1). In panels (E) and (F), the ISF 
baseline value for L-phenylalanine is 0.4 µM (Suppl. Table 3. 2). The data are represented as 
percent of baseline. In panel (D), the plasma baseline value for L-phenylalanine and L-
phenylalanine competing LNAAs (constant input) are 77 and 562 µM [84, 92], respectively. In 
panel (D), the CL refers to a mixture of LNAAs competing with the test amino acid L-
phenylalanine (L-leucine, L-isoleucine, L-tyrosine, L-tryptophan, L-valine, L-histidine and L-
methionine). In Panels (B), (C), (D) and (E), the differences between the concentrations 
calculated with the symmetric model (RKLAT1 = 1 and RELAT1 = 1) and the experimental 
measurements are statistically significant at all post-stimulus time points (p<0.001, Suppl. 
Table 3. 4). In contrast, there is no significant difference between the experimental 
measurements and the model calculations with RKLAT1 = 160 and  RELAT1 = 1 (Panel B), 
RKLAT1 = 1 and  RELAT1 = 0.18 (Panel C), RKLAT1 = 80 and  RELAT1 = 1 (Panel E) and 
RKLAT1 = 0.11 and  RELAT1 = 1 (Panel F) with the exception of the 30 min post-stimulus time 
point in Panels E and F (Suppl. Table 3. 4). 
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Table 3. 1. Model input parameters 
 L-phenylalanineb aetyrosin-L  
Ref. Unit Value Parameters  
    LAT1 (MBEC) 
[25] µM 11 64 Km,abs,LAT1,TL
P(ISF) 
[25, 104] µmol/min 0.075 0.175 Vmax,LAT1,lum,TL 
[25] µM 52.9c 37c Km,abs,LAT1,CL
P(ISF) 
[25, 104] µmol/min 0.129c 0.086c Vmax,LAT1,lum,CL 
    LAT2 (Astrocyte) 
[28] µM 110.2d 294d Km,abs,LAT2,TL
ISF(Ast) 
[59, 105] µmol/min 0.1128 0.1128 Vmax,LAT2,TL 
[28] µM 185.9c 163.6c Km,abs,LAT2,CL
ISF(Ast) 
[59, 105] µmol/min 0.1494c 0.1452c Vmax,LAT2,CL 
    B0AT2 (Neuron) 
[32] µM 1050 NA  Km,abs,B0AT2,TL
ISF(Neu) 
[32, 106] µmol/min 0.0086 NA  Vmax,B0AT2,TL 
[32] µM 126.2c 123.5c Km,abs,B0AT2,CL
ISF(Neu) 
[32, 106] µmol/min 0.0186c 0.0184c Vmax,B0AT2,CL 
[107] µM 1050 1050  Km,B0AT2,Na
ISF(Neu) 
[108] mV  -70 -70  ΔΨ 
[94, 107] mV 0.6 e 0.6 e β 
 [109] mM 141 141 [Na]ISF 
[110] mM 40 40 [Na]Neu 
   Volume 
[109, 111] µl 3.5 VMBEC 
[104, 112] µl 352.6 VISF 
[113, 114] µl 742 VAst 
[114-116] µl 441.7 VNeu 
a In this column, TL and CL represent L-tyrosine and L-tyrosine competing LNAAs, respectively. b In this column, TL and CL represent L-
phenylalanine and L-phenylalanine competing LNAAs, respectively. cThe kinetic parameters for the mixture of L-tyrosine and L-
phenylalanine competing LNAAs are calculated based on Eq.10 (Suppl. Table 3. 1). d The kinetic parameters are calculated based on 
Michaelis-Menten equation. e Estimated based on data by [107] , fig 7.D. NA (not applicable) specifies the large neutral amino acid was not 
reported to be a substrate for the transporter. For calculation of Vmax values, the total rat brain weight, volume and protein content are 
considered 1.81 g [117] , 1737 µl [104]  and 105 mg protein /g brain [118], respectively.     
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We then evaluated whether asymmetric bi-directional kinetics of LAT1 in MBECs could explain 
the slower and less important impact of plasma L-tyrosine perturbation on its ISF concentration 
observed in vivo, compared to our first calculations made assuming symmetric transport 
properties of LAT1. To this end, we varied the ratio of extracellular to intracellular Michaelis-
Menten binding constants of LAT1 in MBECs, named here  RKLAT1, from 1 (representing the 
symmetric bi-directional kinetic) to 1300 (highly asymmetric bi-directional kinetics as described 
for LAT1 in Meier et al. [26] and considered LAT1 to be symmetrically distributed at the BBB 
( RELAT1=1). We calculated the post-stimulus LNAA concentration response and compared the 
results with the in vivo measurements (shown as percentage of baseline in Fig. 3. 2B). Under 
consideration of asymmetric bi-directional kinetics for LAT1 in MBECs, the numerical results 
agreed well with in vivo experimental data, best for a bi-directional kinetic constant of 
RKLAT1=160. Thus, the results obtained with our model support the hypothesis that LAT1 
displays a strong asymmetry in bi-directional kinetics in MBECs.  
We then evaluated the alternative or complementary hypothesis that an asymmetry of LAT1 
expression at the luminal and abluminal membranes of MBECs could explain the observed 
equilibration kinetics. To this end, we varied the LAT1 expression constant at the BBB (RELAT1) 
between 0.01 to 10 (representing highly symmetric abluminal to luminal expression ratio) and 
compared the numerical calculations with the in vivo measurements assuming symmetric bi-
directional kinetics of the MBEC LAT1 ( RKLAT1 = 1) (plotted as percentage of baseline in Fig. 
3. 2C). The error bars associated with model simulations are calculated based on sensitivity 
studies (see Sensitivity analysis section). In contrast to the symmetric case, the numerical 
results obtained for asymmetric transporter expression agreed well with in vivo experimental 
data, best for an expression kinetic constant of RELAT1=0.18 (see Fig. 3. 2C). These results 
are compatible with the hypothesis of a strong asymmetry in the expression of the LAT1 in 
MBECs with lower expression at the abluminal membrane. Taken together, the computational 
model, combined with in vivo measurements supports a functional polarity of MBECs with 
either asymmetry in bi-directional kinetics and/or expression distribution of LAT1 in MBECs.  
Cross-substrate versatility 
We next evaluated whether our conclusion on the functional polarity of MBECs described in 
the previous section depends on the substrate by comparing our calculations with in vivo data 
published by Goldstein 28 and Bongiovanni et al.18 in which the ISF response was measured 
after IP administration of L-phenylalanine in awake rats (Fig. 3. 2F). Just as with the L-tyrosine 
case, the model failed to reproduce the experimental measurements when assuming 
symmetric bi-directional kinetics for LAT1 in MBECs, whereas we found a close match between 
 52 
 
 
our model calculations and experimental measurements assuming asymmetric LAT1 bi-
directional kinetics (best with  RKLAT1 =  80). Similarly, the numerical results obtained when 
assuming an asymmetric transporter expression also agreed well with in vivo experimental 
data, best for an expression kinetic constant of RELAT1= 0.11. Taken together, the comparison 
of model output with experimental measurements supports the hypothesis that the MBECs 
show a functional polarity for both L-tyrosine and L-phenylalanine which could be explained by 
either asymmetric distribution of LAT1 at the luminal and abluminal membranes of the MBECs 
(lower abluminal expression) and/or a strong asymmetry in its bi-directional kinetics in MBECs 
(lower intracellular affinity) as previously shown in Xenopus oocytes.  
To further evaluate the dependence of our results on the asymmetric function of LAT1 
suggested for MBECs, we checked whether considering LAT1 as dominant astrocytic AAT 
instead of LAT2 would modify our conclusion on the functional polarity of the MBECs. 
Calculations presented in the Supplementary material (Supp. Fig. 3. 1) showed that this is not 
the case.  
Calculating the post-stimuli responses in MBECs, astrocytes, and neurons 
The in vivo standard methods have so far not been able to address the effects of plasma LNAA 
perturbations on the dynamics of LNAA concentrations in individual NVU compartments. To 
close this gap, we employed the computational model considering either an asymmetry in bi-
directional kinetics of LAT1 or an asymmetry in the expression pattern of LAT1 in MBECs as 
determined for the best cases in Fig. 3. 2. The dynamic responses of L-tyrosine (TL) and L-
tyrosine competing LNAAs (CL) and of L-Phenylalanine (TL) and its competitor LNAA (CL) in 
MBECs, ISF, astrocytes, and neurons are shown in Fig. 3. 3 and Fig. 3. 4 for asymmetric bi-
directional kinetics and asymmetric expression of LAT1, respectively. The same plasma 
perturbations of the test LNAAs (L-tyrosine or L-phenylalanine) used also for Fig. 3. 2 are 
shown to first propagate into the MBECs (Figs. 3.3A, E and 3.4A, E). The dynamics of this 
propagation depend on the competitions between the test and competing LNAAs through 
MBEC LAT1 and its kinetics for each substrate. Since MBEC LAT1 functions as an antiporter, 
the elevated level of the test LNAA in the MBECs leads to an initial reduction in the MBEC 
level of the competing LNAAs (Figs. 3.3A, E and 3.4A, E). Subsequently, the test and 
competing LNAAs compete for efflux via LAT1 across the abluminal membrane of the BBB 
MBECs and eventually gain entry into the brain ISF in exchange for competing LNAA of the 
ISF (Figs. 3.3B, F and 3.4B, F). The observed delayed response in the concentration of the 
test LNAAs in brain ISF in response to the plasma perturbations is mainly due the low inter-
endothelial affinity of LAT1 (Fig. 3. 3B) and/or a low expression of LAT1 at the abluminal 
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membrane of the BBB (Fig. 3. 4B) both of which would strongly limit the trans-endothelial 
transport of LNAAs across the BBB. Once the test (and competing) LNAAs enter the brain ISF, 
they are differentially co-transported together with sodium ions into neurons via B0AT2 (Figs. 
3.3D, H and 3.4D,H) and exchanged back into the MBECs (Figs. 3.3A,E and 4A,E) and 
astrocytes (Figs. 3.3C,G and 3.4C,G) via LAT1 and LAT2, respectively. The rate of these 
transports depends on LNAA concentration, on that of competitor LNAAs and on the kinetics 
of the transporters expressed at the interface to the other NVU compartments (Table 3. 1). For 
example, LNAA transport from ISF to MBECs is comparably low due to the relatively low 
concentration of the LNAAs compared to their Michaelis-Menten binding affinities (Table 3. 1 
and Suppl. Table 3. 2). As shown in Figs. 3.3C, G and 3.4C, G, astrocytic elevation of the test 
LNAAs is associated with the reduction of intracellular competing LNAAs. This behavior is due 
to the exchange mechanism of LAT2 localized at the membrane of astrocytes. In Figs. 3.3D 
and 3.4D, while L-tyrosine transport is shown not to be mediated by B0AT2 (Table 3. 1), this 
LNAA could nonetheless be transported to some extent into neurons by other, less expressed 
transporters (see Discussion section). Taken together, the difference between the response of 
L-tyrosine and L-phenylalanine results from various factors such as their differing original 
perturbation dynamics in plasma (Figs.3.2 A and D) and the transport kinetics differences of 
the NVU-AATs for these substrates and their competitors (Eq. 13 and Table 3.1). 
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Figure 3.3. The post-stimulus response in MBECs, ISF, astrocytes and neurons after 
intraperitoneal administration (IP) of L-tyrosine and L-phenylalanine for asymmetric bi-
directional kinetics of LAT1 in MBECs. Panels (A),(B),(C) and (D) and (E),(F),(G) and (H) 
show the model calculations for the post-stimulus responses in the NVU individual 
compartments after IP administration of L-tyrosine (RKLAT1 =160 and RELAT1 =1) and L-
phenylalanine (RKLAT1 =80 and RELAT1 =1), respectively. The error bars associated with 
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model calculations indicate standard deviation with respect to concentrations obtained with the 
nominal model parameter set. In panels (A), (B), (C) and (D), CL refers to a mixture of L-
tyrosine competing LNAAs (L-leucine, L-isoleucine, L-phenylalanine, L-tryptophan, L-valine, L-
histidine and L-methionine). In panels (E), (F), (G) and (H), CL indicates a mixture of L-
phenylalanine competing LNAAs (L-leucine, L-isoleucine, L-tyrosine, L-tryptophan, L-valine, L-
histidine and L-methionine). The ISF post-stimulus response for TL in panels (B) and (F) are 
replotted from Figs. 3.2B and 3.2E, respectively. In all panels, the baseline concentration for 
L-tyrosine, L-tyrosine competing LNAAs, L-phenylalanine and L-phenylalanine competing 
LNAAs are reported in Suppl. Table 3. 2.  
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Figure 3.4. The post-stimulus response in MBECs, ISF, astrocytes and neurons after 
intraperitoneal administration (IP) of L-tyrosine and L-phenylalanine for asymmetric 
expression distribution of LAT1 at luminal and abluminal membranes of the BBB. Panels 
(A,B,C,D) and (E,F,G,H) show the model calculations for the post-stimulus responses in the NVU 
individual compartments after IP administration of L-tyrosine (RELAT1 =0.18 and RKLAT1 =1) and 
L-phenylalanine (RELAT1 =0.11 and RKLAT1 =1), respectively. The error bars associated with 
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model calculations indicate standard deviation with respect to concentrations obtained with the 
nominal model parameter set. In panels (A), (B), (C) and (D), CL refers to a mixture of L-tyrosine 
competing LNAAs (L-leucine, L-isoleucine, L-phenylalanine, L-tryptophan, L-valine, L-histidine 
and L-methionine). In panels (E),(F),(G) and (H), CL indicates a mixture of L-phenylalanine 
competing LNAAs (L-leucine, L-isoleucine, L-tyrosine, L-tryptophan, L-valine, L-histidine and L-
methionine). The ISF post-stimulus response for TL in panels B and F are replotted from Figs. 
3.2C and 3.2F. In all panels, the baseline concentration for L-tyrosine, L-tyrosine competing 
LNAAs, L-phenylalanine and L-phenylalanine competing LNAAs are reported in Suppl. Table 3. 
2.  
The trans-stimulation of the test LNAA uptake across the BBB upon ISF 
perfusion with a LAT1 competitive inhibitor 
Finally, we employed the established computational model to investigate the induced effects 
of brain ISF perfusion with 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH, a 
transported competitive inhibitor of LAT1 and LAT2) on the dynamics of test LNAAs in the brain 
ISF [83]. We have shown recently that continues perfusion of 20 mM BCH (~ 2mM local 
concentration near the perfusion probe [76]) into the brain ISF of freely moving mice trans-
stimulates the LAT1 functions at the BBB and consequently changes the dynamics of LNAAs 
in the brain ISF in exchange for the perfused BCH [76]. To mimic the experimental conditions, 
we have prescribed the brain ISF concentration of BCH as constant input to the model 
(considering BCH as competing LNAA (CL) with the same kinetics [83]) and consequently 
calculated the post-stimulus responses in the concentration of test LNAAs. Considering the 
fact that measuring the global concentrations of BCH in the entire brain ISF compartment is 
experimentally challenging, we compared the numerical calculations with the in vivo 
measurements for different values for the global concentrations of BCH which are much lower 
than the local BCH concentrations near the probes. The computational results for the dynamic 
changes of L-tyrosine and L-phenylalanine calculated using the kinetic and expression ratios 
of LAT1 (RKLAT1 and RELAT1) determined above are plotted in Fig. 3. 5A and 5B, respectively 
as percentage of the baseline. The error bars associated with model simulations are calculated 
based on sensitivity studies described below. As shown in all panels, the elevation of perfused 
BCH concentration leads to increased stimulation of the transport of test LNAAs into the brain 
ISF which is due to the stimulated exchange of the perfused BCH with the test LNAAs via 
MBEC LAT1 and astrocyte LAT2 (trans-stimulation of efflux from these cells). The model 
calculations for the stimulated test LNAAs eventually reach a plateau consistent with our 
previous experimental observations. The best match between model and experimental 
measurements was observed for global BCH concentrations of 17-30 µM in the brain ISF. It 
has to be noted that our model, by assuming a homogenous mixture of LNAAs within the 
individual NVU compartments, disregards the delayed diffusion time of the perfused BCH from 
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the probe site into the ISF which already explains the initial difference between model 
calculations and experimental measurements in all panels (see Discussion). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Trans-stimulation of the test LNAA uptake across the BBB during ISF 
perfusion with BCH. Figure 5 shows the ISF concentration of the test LNAAs during ISF 
perfusion with 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) started at time 
zero. In all panels, the experimental data are measured by Dolgodilina et al. [76] for 
trans- stimulation of test LNAA (L-valine) during 170 minute continues ISF perfusion with 
20 mM BCH into a group of freely moving mice (four animals). Panels (A) and (B) show 
the model calculations for L-tyrosine trans-stimulations upon perfusion of BCH with 
different global concentration levels. In panels (A) and (B), the bidirectional kinetic constant 
and the expression ratio of LAT1 are considered, (RKLAT1 = 160, RELAT1 = 1) and (RKLAT1 = 
1,  RELAT1 =0.18), respectively. Panels (C) and (D) show the model calculations for L-
phenylalanine trans-stimulations during perfusion of BCH with different global 
concentration levels in the entire brain ISF compartment. In panels (A) and (B), the bi-
directional kinetic constant and the expression ratio of LAT1 are considered, (RKLAT1 = 
80, RELAT1 = 1) and (RKLAT1 = 1,  RELAT1 =0.11), respectively. The model simulations and the 
experimental data are represented as percent of the baseline value. The error bars associated 
with model calculations indicate standard deviation with respect to concentrations obtained 
with the nominal model parameter set. For all panels, the calculated baseline concentrations 
of the test LNAAs are reported in Suppl. Table 3. 2. The differences between the experimental 
measurements and model calculations with BCH=10 and 100 µM (Panels (A), (B)) as well as 
BCH=5 and 100 µM (Panels (C), (D)) are statistically significant at all post-stimulus time points 
(p<0.001, Suppl. Table 3. 4). In contrast, model calculations with BCH=30 µM (Panels (A), (B)) 
A 
B 
C 
D 
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and BCH=17 µM (Panels (C), (D)) are not significantly different from the experimental 
measurements with the exception of the 20 min post-stimulus time point (Suppl. Table 3. 4). 
Sensitivity analysis and statistical testing 
We assessed the sensitivity of the reported results with respect to the choice of literature-
reported values of model parameters. To accomplish this goal, we simultaneously varied the 
nominal model input parameters (Michaelis-Menten binding constant, maximum transport rate 
of AATs (Table 3. 1) and the initialized baseline concentration of LNAAs in individual 
compartments (Suppl. Table 3. 2) within realistic bounds (± 20% for each parameter), and then 
assessed the model output for 100 random parameter sets. The results of the sensitivity 
analysis are presented in Suppl. Tables 3.2 and 3.3, as well as in Figs. 3.2-5 and Suppl. Fig. 
3.1, where error bars indicate standard deviation of the computed concentrations from those 
obtained under nominal parameter conditions. We then assessed whether differences in the 
set of calculated and experimentally measured concentration profiles are statistically 
significant. To this end, we performed at each post-stimulus time point Student’s unpaired t-
test with Holm-Sidak correction for multiple comparisons using GraphPad Prism 5.0 
(GraphPad Software, USA). P values < 0.01 were considered indicative of statistical 
significance (see Suppl. Table 3. 4 for test results). 
Discussion 
In this study, using a computational model and experimental input data, we obtained results 
that strongly suggest a functional polarity of MBECs for the trans-endothelial transport of 
LNAAs, and characterized a potential strong asymmetry in bi-directional kinetics and/or an 
asymmetry in membrane expression of MBEC LAT1, which could so far not be addressed with 
current standard in vitro and in vivo methods. The robust computational model of NVU-LNAA 
transport we have built and used in this study is based on the fluxes mediated by the respective 
dominant transporters expressed in MBECs, astrocytes and neurons, namely LAT1, LAT2 and 
B0AT2. This allowed us to test different symmetric and asymmetric hypotheses about the bi-
directional kinetics and/or the expression of LAT1 in MBECs. The comparison of our 
computational results with published in vivo microdialysis measurements obtained in rat brain 
supports the hypothesis that MBEC LAT1 either exhibits strong asymmetric bi-directional 
kinetics for LNAAs (lower affinity inside the MBECs) and/or is asymmetrically expressed at the 
BBB (lower expression level at the abluminal membrane relative to the luminal membrane of 
the BBB). This observation is shown to be independent of the substrate considered (i.e. L-
tyrosine and L-phenylalanine).  
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After the characterization of the functional polarity of MBECs, we aimed at understanding the 
response of the individual NVU cells to IP administration of LNAAs, which has not been 
addressed so far by in vivo standard methods. To accomplish this, we employed the 
computational model to calculate the changes in the concentrations of NVU-LNAAs in 
response to IP administration of L-tyrosine and L-phenylalanine, considering asymmetry in 
either bi-directional kinetics and/or expression distribution of LAT1 in MBECs. We thereby 
captured the interactive dynamics of LNAAs as they traverse the blood-brain barrier (BBB) 
from the capillary lumen into the brain interstitial fluid and from there eventually into astrocytes 
and/or neurons. Finally, we employed the model to explain also the trans-stimulation of LNAA 
uptake across the BBB upon ISF perfusion with BCH, a competitive inhibitor of LAT1.  
LAT1 is the primary entry way to the brain for a broad range of the essential LNNAs and their 
analogs, such as L-DOPA, gabapentin and L-melphalan [24, 97, 119]. Hence, our finding of its 
asymmetric kinetics and/or expression in MBECs provides novel insight that may help advance 
our understanding of LAT1-mediated prodrug delivery (i.e. meta-substituted phenylalanine 
prodrugs) to the brain [120-122]. In addition, our computational model could be employed to 
provide insight into the amino acid transport processes in brain disorders associated with 
perturbations of LNAAs in the plasma, e.g. phenylketonuria (PKU) or Maple syrup urine 
disease (MSUD). This could be achieved by using the plasma LNAA perturbations observed 
in patients as input to the model to calculate the corresponding responses in the NVU-LNAA 
concentrations, which are challenging to measure experimentally [123].   
We note a number of simplifying assumptions made for the development of our computational 
model. For instance, the assumption of a homogenous mixture of LNAAs within the individual 
NVU compartments disregards the local differences in the intra-compartmental concentration 
of LNAAs. In reality, however, regional distribution of amino acids in NVU compartments may 
affect the binding of LNAAs to the corresponding transporters, and therefore also the local 
transport fluxes. Moreover, we have considered competitive LNAAs as a single entity rather 
than accounting one by one each individual competitor for the transport of L-phenylalanine or 
L-tyrosine, such as L-leucine, L-tryptophan and others (Suppl. Table 3. 1). This assumption, 
however, has already been experimentally validated for multi-substrate enzymatic reactions 
[124]. In addition, we focused on a single carrier per NVU compartment membrane, specifically 
on the antiporters (obligatory exchangers) LAT1 and LAT2 for MBECs and astrocytes, 
respectively, and a symporter (cotransporter B0AT2) for neurons, not taking into consideration 
diffusive pathways which have been shown, however, to be of lesser importance for LNAAs in 
the NVU [96]. Moreover, we did not include LNAA metabolism, which is not completely known 
and understood in the CNS [125, 126]. However, it has been shown that the brain metabolic 
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fluxes of LNAAs (such as L-phenylalanine, L-histidine, etc) are small compared to the carrier-
mediated fluxes [127]. Additionally, our model relies on literature-reported parameter values, 
which are inevitably associated with the reported uncertainty. Nevertheless, our sensitivity 
analysis has shown that the conclusions drawn in this study hold within reasonable parameter 
variations. Furthermore, it has to be pointed out that the established computational model takes 
only into account the interactions between the dominant NVU-LNAA transporters mentioned 
above and disregards the contribution of other transporters, such as for instance y+LAT2 and 
ASCT2, which have been shown to be expressed in adult brains, though at a lower level [87-
89]. Beyond that, it has to be highlighted that the structure and function of many (SLC) 
transporters have yet to be fully characterized and that some of them may also transport 
LNAAs, such that further research is required [119]. The contribution of newly discovered NVU 
transporters could then be included in the computational model upon sufficient characterization 
of their kinetics. 
Summary  
We have characterized a functional polarity for MBECs which are the key NVU element for the 
control of LNAA homeostasis in the brain ISF. For this purpose, we have developed a robust 
computational model of NVU-LNAA homeostasis and combined it with published in vivo 
measurements obtained in rat brain. We have shown that either strong asymmetrical bi-
directional kinetics of LAT1 in MBECs and/or an asymmetric distribution of LAT1 at both 
membranes of MBECs is required to reproduce available in vivo measurements. This 
conclusion is strengthened by the fact that it is supported by data obtained for two tested 
LNAAs, L-tyrosine and L-phenylalanine. Important characteristics of LAT1 function in MBECs 
have not been tested satisfactorily up to now by experimental means. In addition, based on 
our findings on the functional polarity of MBECs, we employed our computational model to 
investigate the dynamic behavior of LNAAs in astrocytes and neurons in response to IP-
administered L-tyrosine and L-phenylalanine, values which are challenging to determine 
experimentally. Finally, we used the model to explain the trans-stimulation of LNAA uptake 
across the BBB upon ISF perfusion with a LAT1 competitive inhibitor. While we employed our 
computational platform to answer fundamental physiological questions about homeostatic 
regulation of LNAAs in the NVU, it could also be used to test strategies designed to improve 
the treatment and management of LNAA-related brain disorders. 
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Supplementary Table 3.1: The kinetic parameters of the dominant transporters and concentration of 
individual LNAAs in the different brain compartments  
 
Kinetic parameters Concentration 
LAT1 
(MBEC) 
LAT2 
(Astrocyte) 
B0AT2 
(Neuron) 
LAT1 
(MBEC) 
LAT2 
(Astrocyte) 
B0AT2e 
(Neuron) 
Plasma ISF 
Astrocyte and 
neuronf 
(µM)m,abs K (µmol/min)max V Concentration (µM) 
L-phenylalanine 
11 
[25] 
a10.21 
[28] 
1050 
[32] 
0.075 
[25, 104] 
0.1128 
[59, 105] 
0.0193 
[32, 106] 
77 
[84] 
0.73 
[84] 
52.1 
[85] 
L-valine 
210 
[25] 
a10.21 
[28] 
190 
[30, 31] 
0.089 
[25, 104] 
0.1427 
[59, 105] 
0.0193 
[32, 106] 
211 
[84] 
1.22 
[84] 
86.5 
[85] 
L-leucine 
29 
[25] 
224.2 
[28] 
81 
[32] 
0.107 
[25, 104] 
0.184 
[59, 105] 
0.0193 
[32, 106] 
149 
[84] 
1.35 
[84] 
66.7 
[85] 
L-isoleucine 
56 
[25] 
a39.21 
[28] 
58 
[32] 
0.109 
[25, 104] 
0.131 
[59, 105] 
0.0154 
[32, 106] 
102 
[84] 
0.77 
[84] 
26.1 
[85] 
L-histidine 
100 
[25] 
a273 
[28] 
NA 
0.111 
[25, 104] 
0.173 
[59, 105] 
NA 
52 
[84] 
1.12 
[84] 
68.8 
[85] 
L-tyrosine 
64 
[25] 
a942 
[28] 
NA 
0.175 
[25, 104] 
0.113 
[59, 105] 
NA 
112 
[92] 
0.76 
[84] 
76.1 
[85] 
L-tryptophan 
15 
[25] 
a10.21 
[28] 
NA 
0.099 
[25, 104] 
0.131 
[59, 105] 
NA 
17 
[84] 
0.15 
[84] 
13.5 
[99] 
L-methionine 
40 
[25] 
a30.74 
[28] 
40 
[32] 
0.046 
[25, 104] 
0.156 
[59, 105] 
0.0193 
[32, 106] 
96 
[84] 
0.37 
[84] 
38.6 
[85] 
CLbc 37 163.6 123.5 0.0859 0.1452 0.0193 704 5.7 352.2 
CLbd 59.2 185.9 126.2 0.0973 0.1494 0.0193 739 5.7 376.2 
aThe values are calculated based on Michaelis-Menten equation [28, 128] .bThe kinetic parameters for the mixture of competing 
LNAAs are calculated based on Eq.10. c In this row, CL represent the mixture of L-tyrosine competing LNAAs (mixture of L-leucine, 
L-isoleucine, L-phenylalanine, L-tryptophan, L-valine, L-histidine and L-methionine). dIn this row, CL represent the kinetic parameters 
for the mixture of phenylalanine competing LNAAs (mixture of L-leucine, L-isoleucine, L-tyrosine, L-tryptophan, L-valine, L-histidine 
and L-methionine). eThe volume of astrocyte is considered 742 µl [113, 114] (Table 1). eThe reported Vmax values for individual 
LNAAs are based on the Leucine measurements.  f The concentration of LNAAs in the neuron and astrocyte compartments are 
based on measurements in the brain tissue [105]. NA (not applicable) specifies that the large neutral amino acid was not reported 
to be a substrate for the transporter. For calculation of Vmax values, the total rat brain weight, volume and protein content and the 
volume of astrocyte and neuron are considered 1.81 g [117], 1737 µl, 105 mg protein/g brain [118], 742 µl [113, 114] and 441.7 µl 
[114-116] (Table 1), respectively.   
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Evaluation of brain ISF post-stimuli responses under the assumption of LAT1 as the 
dominant LNAA transporter in astrocytes 
As mentioned in the Introduction section, several studies have shown that LAT2 is the 
dominant LNAA transporter in primary astrocyte cells [27-29]. However, Zhang Y, et al. [86] 
showed that freshly isolated astrocytes specifically express higher levels of LAT1 mRNA 
compared LAT2 mRNA [86]. Even though the mRNA expression does not necessarily 
correspond to protein abundance and dominance [83], and although there is no report on the 
astrocytic transport activity of LAT1 in non-cultured cell assays, we have additionally checked 
whether considering LAT1 instead of LAT2 as dominant astrocytic AAT would modify our 
conclusion on the functional polarity of MBECs with either asymmetric bi-directional kinetics 
Supplementary Table 3. 2: The initialization and model calculations for the baseline 
concentration of LNAAs in the individual NVU compartments. 
  bphenylalanine-L atyrosine-L  
Unit 
Calculated baseline       
 concentration 
Initialized 
baseline 
concentrati
con 
Calculated baseline    concentration 
Initialized 
baseline 
cconcentration 
Parameter 
dMicrovascular brain endothelial cell 
 µM 
106.5 ± 13.6 146.8 ± 24.6  [0-52.1] 
[85] 
16.6±1.1 274.0 ± 20.9  [0-76.1] 
[85] 
[TL]b
MBEC 
 µM 
1022.4 ±130.7 1408.8 ± 235.7 [0-376.2] 
[85, 99]  
104.5±6.6 1722.2 ± 131.5 [0-352.2] 
[85, 99] 
[CL]b
MBEC 
 eBrain interstitial fluid 
  µM 
0.4 ± 0.03 0.4 ± 0.03 0.7 
[84]  
1.2±0.1 1.0±0.1 0.8 
[84] 
[TL]b
ISF 
 µM 
3.8 ± 0.3 3.8 ± 0.3 5.7 
[84]  
7.3±0.9 6.5±0.9 5.7 
[84] 
[CL]b
ISF 
fAstrocyte 
 µM 
40.2 ± 4.6 40.6 ± 4.8 52.1 
[85]  
66.1±6.7 61.5 ± 7.0  76.1 
[85] 
[TL]b
Ast 
 µM 
385.7 ± 44 389.7 ± 46.0 376.2 
[85, 99] 
415.5±41.8 386.5± 43.7 352.2 
[85] 
[CL]b
Ast 
fNeuron 
µM 
54.3 ± 6.0 53.4 ± 7.0 52.1 
[85]  
77.1±9.3 75.1 ± 9.0  76.1 
[85] 
[TL]b
Neu 
 µM 
375.2 ± 39.8 368.7 ± 46.9 376.2 
[85, 99] 
354.8±41.3 316.6 ± 41.4   352.2 
[85, 99] 
[CL]b
Neu 
The bi-directional and expression constant of MBEC LAT1 
- 1 80 - 1 160 - RKLAT1 
- 0.11 1 - 0.18 1 - RELAT1 
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and/or asymmetric distribution of LAT1 in MBECs. To this end, we assumed LAT1 to be the 
dominant astrocytic LNAA transporter, replacing LAT2 in the astrocyte. In this situation, given 
that the intra-compartmental fluxes depend on the choice of the dominant transporters, we 
simply substituted the parameters of Eq. (7) (Methods section) with those of LAT1 for 
astrocytes (reported in Suppl. Table 3. 3) and similarly calculated the baseline (pre-stimulus) 
state of the NVU system as reported in Suppl. Table 3. 3. We then calculated the post-stimulus 
response of LNAA concentrations (Suppl. Fig. 3.1) upon perturbation of plasma L-tyrosine and 
L-phenylalanine concentrations (Figs. 3.2A and 3.2C). All model parameters except for kinetic 
parameters specific to LAT1 in the astrocyte (Suppl. Table 3. 3) remain the same as in the 
nominal model (Table 3. 1). The bi-directional kinetic constant for astrocyte LAT1 is considered 
equal to the corresponding value in the MBEC LAT1 ( RKLAT1). The time evolution of the 
plasma concentration of L-tyrosine and L-phenylalanine and of competing LNAAs is plotted as 
percentage of the baseline values in Suppl. Fig. 3. 1. The error bars given for the baseline 
concentrations were calculated based on sensitivity studies as described in the Sensitivity 
analysis section. We compared the model predictions for the ISF response to IP L-tyrosine and 
L-phenylalanine injection with results of in vivo measurements [92, 93], in the range from 1 
(symmetric case) and 1300 (highly asymmetric bi-directional kinetics[26]) (Suppl. Fig. 3.1A,C). 
We found a close agreement between our model calculations and experimental measurements 
assuming asymmetric MBEC LAT1 kinetics (best with  RKLAT1 =  220 and 45, respectively, for 
L-tyrosine and L-phenylalanine IP injection cases), while the model failed to reproduce the 
experimental data when the bi-directional kinetics of LAT1 were assumed to be symmetric in 
MBECs (Suppl. Fig. 3. 1A, C).  
To evaluate the hypothesis of asymmetric distribution of LAT1 at the BBB, we varied the 
abluminal to luminal expression ratio of LAT1, RELAT1 , between 0.01 to 10 (representing highly 
asymmetric abluminal to luminal expression ratio) while we assumed the bi-directional kinetics 
of LAT1 to be symmetric ( RKLAT1 = 1). The numerical results obtained with asymmetric 
transporter expression agreed well with in vivo experimental data, best for an expression 
kinetic constant of RELAT1=0.12. Taken together, our results show that assuming LAT1 rather 
than LAT2 as the dominant astrocytic AAT does not affect our conclusion on functional polarity 
of MBECs with either strong asymmetric kinetics of LAT1 and/or its expression at the BBB. 
Further exploration of the correlation between astrocyte mRNA is required to characterize the 
function of LAT1 in astrocytes in vivo. 
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Supplementary Table 3. 3: The kinetic parameters when assuming LAT1 as the dominant LNAA 
transporter in astrocytes, and the calculated baseline concentration of individual LNAAs in the 
different brain compartments 
 L-phenylalanineb L-tyrosinea  
Unit Value Parameters  
   LAT2 (Astrocyte) 
µM 
11 
[25] 
64 
[25] 
Km,abs,LAT1,TL
ISF(Ast) 
µmol/min 
0.184  
[105] 
0.132  
[105] 
Vmax,LAT1,TL 
µM 
52.9 
 [25] 
37 
[25] 
Km,abs,LAT1,CL
ISF(Ast) 
µmol/min 
0.178c 
[105] 
0.184c 
[105] 
Vmax,LAT1,CL 
 
 
 
Calculated baseline 
concentrationd 
µM 99.7 ±14.7 142.9 ± 24.9 16.8±1.1 281.4 ± 23.9 [TL]b
MBEC 
µM 957 ±140.7 1371.7 ± 238.9 105.8±6.8 1770.9 ±150.3 [CL]b
MBEC 
µM 0.4 ±0.03 0.4 ± 0.03 1.1±0.1 1.0 ± 0.1 [TL]b
ISF 
µM 3.9 ±0.3 3.8 ±0.3 7.1±0.8 6.4 ± 0.8 [CL]b
ISF 
µM 38.4 ±4.4 39.6 ± 4.7 62.4±7 63.0± 7.5 [TL]b
Ast 
µM 368.8 ±42.7 379.5 ±45.3 392.4±44.1 395.7 ± 42.3 [CL]b
Ast 
µM 57.3 ±6.4 54.4 ± 6.6 75.4±8.7 74.6 ± 8.8 [TL]b
Neu 
µM 395 ±43 376.1 ± 44.0 342.9±39.2 308.8 ± 40.8 [CL]b
Neu 
     
The bi-directional and 
expression constant of MBEC 
LAT1 
- 1 45 1 220 RKLAT1  
- 0.12 1 0.12 1 RELAT1 
aIn this column, TL and CL represent L-tyrosine and L-tyrosine competing LNAAs, respectively. bIn this column, TL and CL represent L-
phenylalanine and L-phenylalanine competing LNAAs, respectively. cThe kinetic parameters for the mixture of L-tyrosine and L-phenylalanine 
competing LNAAs are calculated based on Eq.10 (Suppl. Table 3. 1) and the reported Vmax values for individual LNAAs are based on the 
Leucine measurements dThe initialization of baseline concentrations is described in Suppl. Table 3. 2.   
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Statistical analysis 
 
Supplementary Table 3.4: P-values of Student’s unpaired t-test for differences 
between calculated and measured concentrations  
 
 Model parameters Post-stimulus time (min) 
 RKLAT1 
[-] 
RELAT1 
[-] 30 60 90 120 150 180 210 240 
Fig. 2B 
1 1 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 2.38.10-8 
10 1 3.79.10-7 2.45.10-4 7.95.10-3 0.056 0.057 0.057 0.057 0.011 
160 1 0.387 0.035 0.906 0.906 0.906 0.387 0.387 0.387 
1300 1 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 
Fig. 2C 
1 0.01 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 
1 0.18 <10-15 0.235 0.847 0.329 0.149 0.629 0.847 0.149 
1 1 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 2.38.10-8 
1 10 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 5.01.10-10 1.90.10-5 
Fig. 2E 
1 1 <10-15 <10-15 <10-15 <10-15 1.36.10-5 0.972 <10-15 <10-15 
10 1 1.77.10-8 9.60.10-12 1.56.10-11 6.70.10-9 0.013 0.807 8.45.10-5 0.121 
80 1 8.96.10-8 0.990 0.749 0.990 0.047 0.990 0.018 0.826 
1300 1 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 
Fig. 2F 
1 0.01 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 
1 0.11 0.001 0.720 0.720 0.720 0.435 0.720 0.231 0.720 
1 1 <10-15 <10-15 <10-15 <10-15 1.36.10-5 0.972 <10-15 <10-15 
1 10 <10-15 <10-15 <10-15 5.15.10-12 0.024 <10-15 <10-15 <10-15 
  
 System input Post-stimulus time (min) 
 [BCH] [µM] 20 50 80 110 170 
Fig. 5A 
10 <10-15 <10-15 <10-15 <10-15 <10-15 
30 2.94.10-12 0.121 0.662 0.023 0.646 
100 <10-15 <10-15 <10-15 <10-15 <10-15 
Fig.5.B 
10 <10-15 <10-15 <10-15 <10-15 <10-15 
30 1.50.10-8 0.971 0.045 0.971 0.045 
100 <10-15 <10-15 <10-15 <10-15 <10-15 
Fig.5.C 
5 <10-15 <10-15 <10-15 <10-15 <10-15 
17 <10-15 0.135 0.470 0.151 0.492 
10 <10-15 <10-15 <10-15 <10-15 <10-15 
Fig.5.D 
5 <10-15 <10-15 <10-15 <10-15 <10-15 
17 <10-15 0.549 0.071 0.571 0.062 
100 <10-15 <10-15 <10-15 <10-15 <10-15 
  
 Model parameters Post-stimulus time (min) 
 RKLAT1 
[-] 
RELAT1  
[-] 30 60 90 120 150 180 210 240 
Suppl. 
Fig.1.A  
1 1 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 
10 1 3.32.10-7 5.64.10-5 6.63.10-3 0.056 0.057 0.057 0.057 0.011 
220 1 0.139 2.34.10-4 0.029 0.472 0.737 0.472 0.394 0.246 
1300 1 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 
Suppl. 
Fig.1.B 
1 0.01 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 
1 0.12 3.42.10-12 0.623 0.627 0.623 0.011 0.627 0.503 0.503 
1 1 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 
1 10 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 3.31.10-11 
9.66.10-
6 
Suppl. 
Fig.1.C 
1 1 <10-15 <10-15 <10-15 <10-15 8.83.10-7 0.012 0.262 
6.17.10-
4 
10 1 7.21.10-11 2.40.10-8 1.71.10-8 1.03.10-5 1.62.10-4 2.90.10-4 0.018 
1.58.10-
4 
45 1 0.032 4.35.10-9 0.223 0.032 0.045 0.013 0.535 0.017 
1300 1 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 
Suppl. 
Fig.1.D 
1 0.01 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 <10-15 
1 0.12 0.025 0.011 0.758 0.719 0.758 0.204 0.758 0.088 
1 1 <10-15 <10-15 <10-15 <10-15 8.83.10-7 0.012 0.262 
6.17.10-
4 
1 10 <10-15 <10-15 <10-15 7.36.10-11 0.023 0.030 9.05.10-11 <10-15 
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Supplementary Figure 3.1. The brain ISF concentration response after intraperitoneal 
injection of L-tyrosine and L-phenylalanine under the assumption of LAT1 as the 
dominant LNAA transporter in astrocytes. Panels (A) and (B) show the experimental data 
for L-tyrosine (Tyr) concentration in the brain ISF (prefrontal cortex (PFC)) [92] in response to 
IP administration of 200 mg/kg L-tyrosine (as plotted in Fig. 3.2B) compared to the model 
calculations assuming LAT1 as the dominant transporter in astrocytes (model input as shown 
in Fig. 3.2A) for various ratios of the bi-directional kinetic constant of LAT1 in MBEC and 
astrocytes (RKLAT1) as well as different abluminal to luminal expression ratio of LAT1 (RELAT1). 
In Panels (A) and (B), the ISF baseline values for L-tyrosine are 1.0 and 1.1 µM (Suppl. Table 
3. 3), respectively. Each experimental data point represents the mean ± SD for three (plasma) 
and four to eight (ISF) animals [92]. The error bar associated with model calculations indicate 
the standard deviation determined based on the sensitivity analysis results. Panel (C) and (D) 
show the experimental data for L-phenylalanine (Phe) concentration in the brain ISF (prefrontal 
cortex (PFC)) [93] in response to IP administration of 200 mg/kg L- phenylalanine (as plotted 
in Fig. 3.2D), versus the model calculations (model input is shown in Fig. 3.2D) for various 
ratios of the bi-directional kinetic constant of LAT1 in MBEC and astrocytes (RKLAT1) as well 
as different abluminal to luminal expression ratios of LAT1 (RELAT1). In panels (C) and (D), the 
ISF baseline value for L-phenylalanine is 0.4 µM as reported in Suppl. Table 3. 3. In Panels 
(A), (B), (C) and (D), the differences between the output of the symmetric model (RKLAT1 = 1 
and RELAT1 = 1) and experimental measurements are statistically significant at all post-
stimulus time points (p<0.001, Suppl. Table 3. 4) with the exception of 180 and 210 min in 
Panels (C) and (D). In contrast, there is no significant difference between the experimental 
measurements and the model calculations with RKLAT1 =220 and  RELAT1 = 1 (Panel A), 
RKLAT1 = 1 and  RELAT1 = 0.12 (Panels (B) and (D)), and RKLAT1 = 45 and  RELAT1 = 1 (Panel 
C), with the exception of the 30 min post-stimulus time point in Panel (B) and the 60 min point 
in Panels (A) and (C) (Suppl. Table 3. 4). 
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Chapter 5 Conclusion and outlook 
Conclusion 
The focus of this doctoral thesis is to establish a combined computational and 
experimental framework of AAT interactions to investigate the regulation of amino 
acids (AAs) across cell membranes. The first part of the thesis (chapter 2) introduced 
an integrated in vitro and in silico approach that enables unraveling the contributions 
of specific players in a complex cellular network of AAs and AATs at single 
membranes. The second part (chapter 3) described a combined in vivo and in silico 
approach to investigate the dynamic interactions between large neutral amino acid 
(LNAA) transporters located at the membranes of neurovascular unit (NVU) cells. The 
third part (chapter 4), presented an application for the in silico model of large neutral 
amino acid (LNAA) homeostasis in the NVU to gain some insights into the regulatory 
role of brain LNAA transporters involved in Phenylketonuria (PKU) disorder. 
In chapter 2, we provided a robust and versatile tool based on a systems biology 
approach to characterize the contributions of specific AAT to overall cellular transport, 
using limited experimental input. Using this approach, we could accurately predict the 
cellular transport responses to new stimuli in presence and absence of extracellular 
sodium ions and different competitive inhibitors. We applied this strategy to quantify L-
leucine and L-phenylalanine individual AATs expressed in X. leavis oocyte in vitro. 
However, given the appropriate assay conditions, this methodology is also applicable 
to other enzymes, substrates, and/or cellular systems where the kinetics of each active 
enzyme species in the system can be described by the Michaelis–Menten equation.  
While the main strength of our approach is its capability to quantify the activity of 
individual transporters that function within a complex network of transporters, it is 
limited to the investigation of the trans-membrane transport processes through single 
membranes and under steady state conditions where the MM assumptions are valid.   
In chapter 3, we further extended our mathematical model beyond the Michaelis–
Menten kinetics to represent dynamics of AATs interactions through multiple cell 
membranes. We have targeted the NVU-LNAA transport system to get more insight 
on mechanisms that maintain the homeostasis of LNAAs in the NVU individual cells, 
such as microvascular brain endothelial cells (MBECs), astrocytes and neurons. By 
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incorporation of published in vivo microdialysis measurements obtained in rat brain into 
our newly developed in silico model, we have shown that either strong asymmetrical 
bi-directional kinetics of LAT1 in MBECs (lower affinity inside the MBECs) and/or an 
asymmetric distribution of LAT1 at both membranes of MBECs (lower expression at 
the abluminal membrane of the BBB) is required to reproduce published in vivo 
measurements. Our conclusion is supported by data obtained for two different LNAAs, 
L-tyrosine and L-phenylalanine. This vital characteristic of LAT1 function in MBECs 
could not be addressed satisfactorily up to now by available in vivo and in vitro standard 
assays.  LAT1 plays a crucial role in regulating the import and export of a large number 
of substrates including some prodrugs such as L-DOPA in and out of the brain. 
Therefore, our observations for its asymmetric kinetics and/or expression could shed 
lights on LAT1 mediated prodrug delivery across the BBB [120-122]. On the basis of 
our findings about the function of LAT1 across the BBB, we furthure investigated the 
dynamics of LNAAs concentrations in MBECs, brain ISF, astrocytes and neurons in 
response to IP-administered L-tyrosine and L-phenylalanine, values which are difficult 
and challenging to determine experimentally. Finally, we used our model to explain the 
trans-stimulation of LNAA uptake across the blood brain barrier (BBB) upon interstitial 
application of BCH (2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid), a LAT1 
competitive inhibitor. Taken together, our developed in silico model of NVU-LNAA 
homeostasis is shown to circumvent some limitations associated with the available in 
vivo and in vitro experimental approaches. Our computational model, however, is not 
limited to study the cases we reported and it could be further served to mimic more 
experimental situations. For instance, it can be used to capture the impact of inhibition 
of LAT1 at the luminal and abluminal membranes of the BBB and/or LAT2 in astrocytes 
and/or B0AT2 in neurons, through supplementation of different physiological and non-
physiological substrates and thereby to provide a quantitative representation for the 
corresponding dynamic changes in concentrations of LNAAs in cells of NVU.  
In chapter 4, using our NVU-LNAA homeostasis model, we further extended our study 
to unravel the regulatory role of individual LNAA-NVU transporters in the propagation 
of abnormal perturbations of Phe from plasma into the NVU individual cells in 
Phenylketonuria (PKU) disease. We suggested that plasma Phe fluctuations can 
potentially propagate into the NVU and change there the concentration of LNAAs, with 
the highest magnitude of this effect at low frequency and high amplitude-to-mean ratio 
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of the plasma Phe concentration fluctuations. Failure of AA homeostasis in general 
harmfully affects cell function [150]. In the NVU individual cells, Phe and CL are 
involved in a variety of processes, including the synthesis of essential 
neurotransmitters such as serotonin (5‐hydroxytryptamine; 5‐HT) and dopamine (3-
hydroxytyramine) [151-154], and the production of proteins and lipids (i.e., myelin) 
[125, 126], although their function in the latter processes is not completely 
characterized. Therefore, depending on the full set of function of Phe and CL, 
fluctuations of their concentrations in the NVU could have a negative impact on the 
brain function. Finally, we explained the therapeutic impact of LNAAs supplementation 
in attenuating the disturbed concentrations of Phe and CL in the MBECs, ISF, 
astrocytes and neurons in PKU disorder towards normal physiologic levels, something 
out of reach of in vivo techniques. It has to be pointed out while our in silico model has 
been employed in PKU disease, it could potentially be applied to provide new insights 
into the pathophysiology of other metabolic disorders affecting the brain, such as 
Maple syrup urine disease (MSUD), that are sensitive to the plasma levels of LNAAs 
[123].  
In conclusion, given the inherent functional complexities associated with the behaviour 
of AAT systems, there are technological hurdles that need to be overcome to enable 
corresponding experiments. As an alternative approach, this thesis demonstrates the 
capabilities of integration of in silico with in vitro and in vivo methods to go around these 
hurdles and thereby to provide novel insight into the physiological aspects of AAT 
systems.  
 
Outlook 
The computational models we have developed in this thesis as any other model have 
their simplifications and limitations that are clearly mentioned in each chapter. In 
particular, the computational models rely on literature-reported parameter values, 
which are inevitably associated with the reported uncertainty. We handled this 
limitation through performing sensitivity analysis for each model and demonstrated that 
the conclusions drawn in this thesis hold within the reported reasonable parameter 
variations. Also, as it is a common characteristic of biological models, we have built 
our in silico frameworks based on a simplified anatomy of understudied transport 
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systems. For instance, we have modeled the NVU systems as four compartments (i.e. 
MBECs, brain ISF, astrocyte and neuron) in which the distribution of LNAAs is 
considered to be homogenous. In reality, however, regional distribution of AAs may 
affect their binding efficiency to the corresponding AATs, and therefore also the local 
transport fluxes. On the other hand, there is hope that upon the progress in imaging 
and biochemistry techniques more information about the local distribution of AAs as 
well as the cell morphology will be provided in the near future. This evolution might 
enhance our knowledge about different AAT systems and would allow for more detailed 
investigation of these systems in more precise biological morphologies. Furthermore, 
we focused on a single dominant LNAA transporter per membrane of NVU cells (i.e. 
LAT1 for MBECs, LAT2 for astrocytes and B0AT2 for neurons), and thus disregarded 
the pathways related to diffusion and also NVU transporters with low levels of 
expression, whose impacts have been shown, however, to be insignificant for LNAAs 
in the NVU  [96, 127]. Moreover, it has to be pointed out that our computational models 
are developed based on the available literature about the identified AATs and the 
structure and kinetics of many SLC transporters, including AATs, have yet to be fully 
characterized, such that further research is required. The contribution of newly 
discovered AATs, upon appropriate investigation of their kinetic functions, could then 
be included in our developed computational models. 
It has to be emphasized that the approaches developed in this thesis are not limited to 
the study AAT systems, but they theoretically could be applied to a variety of SLC 
transport systems functioning in different cell types. For example, our systems biology 
approach described in chapter 2) could be employed to quantify the relative 
contribution of a specific SLC peptide (or drug) transporter within a complex network 
of peptides (or drugs) and SLC transporters functioning at single membranes. Our 
integrated in silico and in vivo approach described in chapter 3, for example, could 
potentially be applied to get more insights into the regulatory roles of SLC glucose (or 
drug)  transporters in the maintenance of glucose (or drug) homeostasis in the NVU. 
Moreover, our computational approaches can potentially be used to study SLC 
transport processes across various biological systems such as kidney, intestine, etc. 
Similar to the situation we faced with NVU-LNAA transport systems, this would 
significantly depend on the availability of sufficient in vivo experimental data including 
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results of dynamic time course measurements of concentration changes of the 
considered substrates, such as AAs, peptide, etc as well as on accurate information 
about the kinetics of the expressed SLC transporters. Taken together, our studies 
provide several examples of integrating computational and experimental approaches 
for studying SLC transport complex systems and demonstrate how this integration 
could be an excellent asset for basic and applied research. 
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